NZ713051B2 - S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis - Google Patents
S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis Download PDFInfo
- Publication number
- NZ713051B2 NZ713051B2 NZ713051A NZ71305114A NZ713051B2 NZ 713051 B2 NZ713051 B2 NZ 713051B2 NZ 713051 A NZ713051 A NZ 713051A NZ 71305114 A NZ71305114 A NZ 71305114A NZ 713051 B2 NZ713051 B2 NZ 713051B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- oxprenolol
- composition
- lateral sclerosis
- amyotrophic lateral
- individual
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 272
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 title claims abstract description 171
- 239000002876 beta blocker Substances 0.000 title abstract description 124
- 229960004570 oxprenolol Drugs 0.000 claims abstract description 158
- 150000003839 salts Chemical class 0.000 claims abstract description 129
- 239000011780 sodium chloride Substances 0.000 claims abstract description 129
- CEMAWMOMDPGJMB-UHFFFAOYSA-N Laracor Chemical group CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 claims abstract description 128
- 230000004083 survival Effects 0.000 claims abstract description 50
- 201000010099 disease Diseases 0.000 claims description 44
- 201000010901 lateral sclerosis Diseases 0.000 claims description 42
- 201000000585 muscular atrophy Diseases 0.000 claims description 21
- 206010028289 Muscle atrophy Diseases 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 15
- 201000002241 progressive bulbar palsy Diseases 0.000 claims description 14
- 230000002354 daily Effects 0.000 claims description 12
- 230000000366 juvenile Effects 0.000 claims description 2
- 230000002035 prolonged Effects 0.000 claims description 2
- 230000003111 delayed Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 abstract description 32
- 229940068196 placebo Drugs 0.000 description 81
- 239000000902 placebo Substances 0.000 description 81
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 60
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 56
- 229960004181 riluzole Drugs 0.000 description 55
- 229940072169 Rilutek Drugs 0.000 description 52
- 210000003205 Muscles Anatomy 0.000 description 46
- -1 ncbivolol Chemical compound 0.000 description 37
- 230000035492 administration Effects 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 32
- 235000019197 fats Nutrition 0.000 description 29
- 230000000694 effects Effects 0.000 description 25
- 229960002370 Sotalol Drugs 0.000 description 17
- ZBMZVLHSJCTVON-UHFFFAOYSA-N Sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 17
- 229960001035 BOPINDOLOL Drugs 0.000 description 16
- 229960002781 Bisoprolol Drugs 0.000 description 16
- VHYCDWMUTMEGQY-UHFFFAOYSA-N Bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 16
- UUOJIACWOAYWEZ-UHFFFAOYSA-N Bopindolol Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 16
- PHUTUTUABXHXLW-UHFFFAOYSA-N Pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 16
- 229960002508 pindolol Drugs 0.000 description 16
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 15
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 15
- 229960002274 Atenolol Drugs 0.000 description 15
- NWIUTZDMDHAVTP-UHFFFAOYSA-N Betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 15
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N Levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 15
- 229960000831 Levobunolol Drugs 0.000 description 15
- 229960004324 betaxolol Drugs 0.000 description 15
- 229960004605 timolol Drugs 0.000 description 15
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (1R,1'R)-2,2'-iminobis{1-[(2R,2'S)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]ethanol} Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 14
- 229960001222 Carteolol Drugs 0.000 description 14
- LWAFSWPYPHEXKX-UHFFFAOYSA-N Carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 14
- 229960002320 Celiprolol Drugs 0.000 description 14
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 14
- MPQWSYJGFLADEW-UHFFFAOYSA-N Medroxalol Chemical compound C=1C=C2OCOC2=CC=1CCC(C)NCC(O)C1=CC=C(O)C(C(N)=O)=C1 MPQWSYJGFLADEW-UHFFFAOYSA-N 0.000 description 14
- BQIPXWYNLPYNHW-UHFFFAOYSA-N Metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 description 14
- 229960002704 Metipranolol Drugs 0.000 description 14
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 14
- 229960004255 Nadolol Drugs 0.000 description 14
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N Nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 14
- 229960003745 esmolol Drugs 0.000 description 14
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 14
- 229950008578 medroxalol Drugs 0.000 description 14
- 229960000619 nebivolol Drugs 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 229960002237 Metoprolol Drugs 0.000 description 13
- IUBSYMUCCVWXPE-UHFFFAOYSA-N Metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 13
- SGUAFYQXFOLMHL-UHFFFAOYSA-N Labetalol Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 12
- 229960001632 labetalol Drugs 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 description 11
- 229950005341 Bucindolol Drugs 0.000 description 11
- NPAKNKYSJIDKMW-UHFFFAOYSA-N Carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 11
- KQXKVJAGOJTNJS-HNNXBMFYSA-N Penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 229960004195 carvedilol Drugs 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 229960002035 penbutolol Drugs 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 229960002122 Acebutolol Drugs 0.000 description 9
- GOEMGAFJFRBGGG-UHFFFAOYSA-N Acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 9
- 201000008752 progressive muscular atrophy Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 206010061818 Disease progression Diseases 0.000 description 8
- 208000005264 Motor Neuron Disease Diseases 0.000 description 8
- 206010028003 Motor neurone disease Diseases 0.000 description 8
- JWHAUXFOSRPERK-UHFFFAOYSA-N Propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 230000000750 progressive Effects 0.000 description 8
- 229960000203 propafenone Drugs 0.000 description 8
- 206010013975 Dyspnoeas Diseases 0.000 description 7
- 210000002161 Motor Neurons Anatomy 0.000 description 7
- 208000010428 Muscle Weakness Diseases 0.000 description 7
- 206010028372 Muscular weakness Diseases 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drugs Drugs 0.000 description 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 7
- 206010002027 Amyotrophy Diseases 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 241000229754 Iva xanthiifolia Species 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 210000000278 Spinal Cord Anatomy 0.000 description 5
- 229940035295 Ting Drugs 0.000 description 5
- 230000003293 cardioprotective Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001809 detectable Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 201000010874 syndrome Diseases 0.000 description 5
- 210000000577 Adipose Tissue Anatomy 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- 210000003414 Extremities Anatomy 0.000 description 4
- 208000005468 Juvenile Amyotrophic Lateral Sclerosis 2 Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000008238 Muscle Spasticity Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229940032147 Starch Drugs 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000003137 locomotive Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000000546 pharmaceutic aid Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010069681 Monomelic amyotrophy Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 206010028347 Muscle twitching Diseases 0.000 description 3
- 210000004165 Myocardium Anatomy 0.000 description 3
- 206010042434 Sudden death Diseases 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide Dismutase Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 230000000271 cardiovascular Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 230000004634 feeding behavior Effects 0.000 description 3
- 238000009459 flexible packaging Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000020763 muscle atrophy Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000001374 small-angle light scattering Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003442 weekly Effects 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- 210000003486 Adipose Tissue, Brown Anatomy 0.000 description 2
- 108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 description 2
- 229920002799 BoPET Polymers 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 206010006542 Bulbar palsy Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000000264 Deglutition Disorders Diseases 0.000 description 2
- FASDKYOPVNHBLU-SSDOTTSWSA-N Dexpramipexole Chemical compound C1[C@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-SSDOTTSWSA-N 0.000 description 2
- 206010013950 Dysphagia Diseases 0.000 description 2
- 208000001308 Fasciculation Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000005041 Mylar™ Substances 0.000 description 2
- QNTASHOAVRSLMD-FCARAQADSA-N Olesoxime Chemical compound C1CC2=C\C(=N/O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNTASHOAVRSLMD-FCARAQADSA-N 0.000 description 2
- 206010061536 Parkinson's disease Diseases 0.000 description 2
- 208000003715 Parkinsonian Disorders Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 210000003019 Respiratory Muscles Anatomy 0.000 description 2
- 102100004434 SETX Human genes 0.000 description 2
- 101700037967 SETX Proteins 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- BHTRKEVKTKCXOH-LBSADWJPSA-N Tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 125000005336 allyloxy group Chemical group 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Inorganic materials [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000000926 neurological Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 201000004193 respiratory failure Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000001148 spastic Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000000152 swallowing Effects 0.000 description 2
- 230000001975 sympathomimetic Effects 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 230000002110 toxicologic Effects 0.000 description 2
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2R)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 1
- FNEJKCGACRPXBT-UHFFFAOYSA-N 2-prop-2-enoxyphenol Chemical compound OC1=CC=CC=C1OCC=C FNEJKCGACRPXBT-UHFFFAOYSA-N 0.000 description 1
- SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 102100001764 ALS2 Human genes 0.000 description 1
- 101700045037 ALS2 Proteins 0.000 description 1
- 102100018024 ANG Human genes 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 240000000800 Allium ursinum Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229940063655 Aluminum stearate Drugs 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- SGEIEGAXKLMUIZ-CYBMUJFWSA-N Arimoclomol Chemical compound C([C@H](O)CN1CCCCC1)ON=C(Cl)C1=CC=C[N+]([O-])=C1 SGEIEGAXKLMUIZ-CYBMUJFWSA-N 0.000 description 1
- 229950011582 Arimoclomol Drugs 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- 206010003658 Atrial fibrillation Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000000133 Brain Stem Anatomy 0.000 description 1
- 229940077737 Brain-Derived Neurotrophic Factor Drugs 0.000 description 1
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 description 1
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 description 1
- 240000001546 Byrsonima crassifolia Species 0.000 description 1
- 235000003197 Byrsonima crassifolia Nutrition 0.000 description 1
- 101700067048 CDC13 Proteins 0.000 description 1
- JEWJRMKHSMTXPP-WZHZPDAFSA-L CHEBI:25291 Chemical compound C([C@]1(C)[C@H]([C@@H]2[C@]3(C)[N+]4=C([C@H]([C@]3(C)CC(N)=O)CCC(N)=O)C(=C3[N+]5=C([C@H]([C@]3(C)CC(N)=O)CCC(N)=O)C=C3[N+]6=C([C@H](C3(C)C)CCC(N)=O)C(=C1N2[Co-3]6541C)C)C)CC(N)=O)CC(=O)NC[C@@H](C)OP([O-])(=O)O[C@@H]([C@H]2O)[C@@H](CO)O[C@@H]2N2C(C=C(C)C(C)=C3)=C3[N+]1=C2 JEWJRMKHSMTXPP-WZHZPDAFSA-L 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 229960004755 Ceftriaxone Drugs 0.000 description 1
- 210000003710 Cerebral Cortex Anatomy 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 208000006111 Contracture Diseases 0.000 description 1
- 229960004826 Creatine Monohydrate Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 210000000188 Diaphragm Anatomy 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 210000001097 Facial Muscles Anatomy 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020745 Hyperreflexia Diseases 0.000 description 1
- 102100014231 IGF1 Human genes 0.000 description 1
- 101700074337 IGF1 Proteins 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N Isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 210000003141 Lower Extremity Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
- 210000002460 Muscle, Smooth Anatomy 0.000 description 1
- VLSTXUUYLIALPB-UHFFFAOYSA-N N-propan-2-ylpropan-1-amine Chemical compound CCCNC(C)C VLSTXUUYLIALPB-UHFFFAOYSA-N 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 210000002682 Neurofibrillary Tangles Anatomy 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229950001051 Olesoxime Drugs 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229940068918 Polyethylene Glycol 400 Drugs 0.000 description 1
- 229960003089 Pramipexole Drugs 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000002804 Pyramidal Tracts Anatomy 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N Pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- 210000003625 Skull Anatomy 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 description 1
- 229950004608 Talampanel Drugs 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 229960003433 Thalidomide Drugs 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N Tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 210000001364 Upper Extremity Anatomy 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 208000003663 Ventricular Fibrillation Diseases 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- UZBODILCSLUHQR-JLMRSGIVSA-N Zenvia Chemical compound C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21.C1C([C@H](C2)C=C)CCN2[C@H]1[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 UZBODILCSLUHQR-JLMRSGIVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 230000002493 climbing Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000001149 cognitive Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001010 compromised Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 230000003205 diastolic Effects 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000021271 drinking Nutrition 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000000626 neurodegenerative Effects 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003190 poly( p-benzamide) Polymers 0.000 description 1
- 229920001485 poly(butyl acrylate) polymer Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229950010601 pramipexole dihydrochloride monohydrate Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000025185 skeletal muscle atrophy Effects 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000001962 taste-modifying agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 230000002747 voluntary Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof. ight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
Description
S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS
FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS
CROSS—REFERENCE TO RELATED APPLICATIONS
This application claims the ty hene lit ol‘ US. Provisional Patent
Application Serial No. 61/786,235, filed March 14. 2013, which, is incorporated herein by
reference in its entirety.
TECHNICAL FIELD
The present invention relates to S—enantiomcrically enriched compositions of
beta blockers or pharmaceutically acceptable salts thereof and uses thereof, ing uses of
the beta blocker compositions for treating ophic lateral sclerosis. The beta blocker can
be oxprenolol or a phannaceutically able salt thereof.
BACKGROUND
Amyotrophic lateral sclerosis (ALS) covers a spectrum of neurodegenerative
syndromes terized by progressive muscular paralysis reflecting degeneration of motor
neurons in the brain and spinal cord. ALS is one of the most common neurodegenerative
disorders, with an incidence of l to 2 per 100,000 and a prevalence 014 to 6 per 100,000; as
many as 30,000 Americans have the disease at any given time (Worms PM. The
epidemiology of motor neuron e: a review of recent studies. .1 Nenrol Sci 2001, 191 :3-
9). The incidence in males is higher than in females (1.6: 1). 5—10% of ts have a
positive family history of ALS, most ly with an autosomal dominant inheritance
pattern. ALS is a disease of mature . with a median age of onset ol‘55 years and its
frequency increases with age until age 75. Overall 50% of patients die within the first three
years since the first clinical manifestations. Apart from age or a positive family history, a
number of factors and enviromnental toxins have been further studied as risk factors. A high
relative risk was described in smokers, soccer players, al 1y Italians and veterans ofthe
Gulf War.
Oxprenolol is a non-selective beta blocker which possesses some intrinsic
sympathomimetic activity. e of its beta blocker function, oxprenolol has been used for
the treatment of various diseases such as angina pectoris, abnormal heart rhythms. and high
blood pressure. ()xprenolol is lipophilic and crosses the blood-brain barrier more easily than
other more water soluble beta blockers. As a result, oxprenolol is associated with a bi0 er
incidence of CNS—related side effects than other beta blockers‘ but also has more central CNS
modes of action.
The disclosure of all publications, patents, patent applications, and published
patent applications referred to herein are hereby incorporated herein by reference in their
entirety.
BRIEF SUMMARY OF THE INVENTION
The present invention relates to tiomerically enriched compositions of
beta blockers or pharmaceutically acceptable salts thereof and uses thereof. including uses of
the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta r can
be oxprenolol or a pharmaceutically able salt thereof.
The present disclosure provides, in some embodiments, a method of treating
amyotrophic lateral sclerosis in an dual having amyotrophic lateral sclerosis,
comprising administering to the individual an effective amount of a composition comprising
a beta blocker or a pharrnaceutically acceptable salt thereof, wherein beta blocker has one
chiral center and the composition is enantiomerically enriched for the tiomer.
The present disclosure es, in some embodiments, a method of
prolonging survival of an individual having amyotrophic lateral sclerosis, comprising
administering to the individual an effective amount of a composition comprising a beta
blocker or a pharmaceutically able salt thereof, wherein beta blocker has one chiral
center and the composition is enantiomerically enriched for the S-enantiomer.
The present disclosure provides, in some embodiments. a method aying
the development ofamyotrophic lateral sclerosis in an individual having amyotrophic lateral
sclerosis, comprising administering to the individual an effective amount of a composition
comprising a beta blocker or a pharmaceutically acceptable salt thereof, wherein beta blocker
has one chiral center and the ition is enantiomerieally enriched for the S-enantiomer.
The present disclosure provides, in some ments a method of
preventing loss of lean mass of an dual having amyotrophic lateral sclerosis,
comprising administering to the dual an effective amount ot‘a composition comprising
a beta blocker or a pharmaceutically acceptable salt thereof. wherein beta blocker has one
chiral center and the composition is cnantiomerically ed for the S-enantiomer.
Ix.)
|0011| The t disclosure provides, in some embodiments, a method of
preventing muscle wasting of an individual having amyotrophic lateral sclerosis, comprising
administering to the individual an ive amount of a composition comprising a beta
blocker or a phannaceutically acceptable salt thereof, wherein beta blocker has one chiral
center and the composition is enantiomerieally enriched for the tiomen
“1012] The present disclosure es, in some embodiments, a method of
improving quality of life in an individual having amyotrophic lateral sclerosis, comprising
administering to the dual an effective amount of a ition comprising a beta
blocker or a pharmaceutically acceptable salt f, wherein beta r has one chiral
center and the composition is enantiomerically enriched for the S~enantiomer
In some embodiments, the beta blocker is oxprenolol or a pharmaceutically
acceptable salt thereof. In some embodiments, the beta blocker is oxprenolol or a
pharmaceutically acceptable salt thereof, wherein the composition is enantiomerieally
enriched for S-oxprenolol. In some embodiments, the composition comprises an
enantiomeric excess of at least about 50% of S—oxprenolol. in some embodiments, the
composition comprises an enantiomerie excess of at least about 80% ofS-oxprenolol. In
some embodiments, the composition comprises an enantiomeric excess of at least about 99%
of S—oxprenolol. In some embodiments, the composition comprises an enantiomerie excess
of at least 99.9% ol‘S-oxprenolol. In some embodiments, the amyotrophic lateral sclerosis is
sporadic amyotrophic l sclerosis. in some embodiments, the ophic lateral
sclerosis is al amyotrophic lateral sclerosis. In some embodiments, the amyotrophic
lateral sclerosis is Western Pacific amyotrophic lateral sis. In some ments, the
amy‘otrophic lateral sis is juvenile amyotrophie lateral sclerosis. In some embodiments,
the amyotrophic lateral sclerosis is Hiramaya Disease. In some embodiments, the
amyotrophic lateral sclerosis is ssive bulbar palsy (PBP), progressive muscular atrophy
(PMA), primary lateral sclerosis (PLS), or ALS with multi—system involvement. In some
embodiments, the composition is administered orally. In some embodiments, the amount of
S—oxprenolol in the composition is about 80 to about 160 mg daily. In some embodiments,
the composition is administered daily or twice daily.
The present disclosure provides, in some embodiments, a k it comprising a
pharmaceutical composition comprising a composition comprising a beta blocker or a
ceutieally acceptable salt thereof, wherein beta blocker has one chiral center and the
composition is enantiomerical 1y enriched for the S-enantiomer; and a pharmaceutically
acceptable carrier for treating amyotrophic lateral sclerosis. In some embodiments. the beta
r is oxprenolol.
BRIEF DESCREPTION OF THE S
Figure l is a diagram showing a clinical symptomatological evaluation of the
BGSJL-'l‘g(SOl)l“‘G93A)lGur/.l ALS transgenic mouse.
Figure 2 is a graph showing the percent survival of mice tions that were
stered with S—oxprenolol or a placebo (plac). The sample size in the population is
indicated by “n."
Figure 3 is a graph showing the percent survival of mice populations that were
administered S—oxprenolol. S-pindolol, or a placebo. The sample size in the population is
indicated by “n.” “HR” refers to hazard ratio. “CI” refers to confidence interval. “95% CI”
is 95% confidence interval. “p” refers to p-value.
Figure 4 is a graph showing the percent survival of mice populations that were
administered S—oxprenolol ), R-oxprenolol (roxlO). oxprenolol (0x20), riluzole
(riluzole), propanolol (prop), or a o (plac). The sample size in the population is
ted by “11.“ “HR” refers to hazard ratio. “CI” refers to confidence interval. “95% CI”
is 95% confidence interval. “p” refers to p-value.
Figure 5 is a graph showing the change in body weight per survival day alter
ALS onset of mice populations that were administered with various dosages of the S-
oxprenolol, S-pindolol, or a placebo. The sample size in the population is indicated by “n.”
Figure 6 is a graph showing the change in lean body mass (in grams (“g")) of
mice populations that: were administered with S-oxprenolol or a o.
Figure 7 is a graph showing the change in lean body mass per survival day
after Al..S onset of mice populations that were administered with S-oxprenolol, S-pindolol, or
a placebo. The asterisk (*) indicates that the p value is less than 0.05 versus placebo.
Figure 8 is a graph showing the mass of gastrocnemius muscle (in grams
("‘g”)) in mice populations that were administered a placebo.
Figure 9 is a graph showing the mass of gastrocnemius muscle (in grams
(“g”)) in, mice populations that were administered enolol.
Figure 10 is a graph showing the mass of tibialis or muscle (in grams
(“g”)) in mice populations that were stered a placebo.
Figure 11 is a graph showing the mass of tibialis anterior muscle (in grams
(“g“)) in mice populations that were administered S—oxprenolol.
Figure 12 is a graph showing the change in fat mass (in grams (“g”)') of mice
populations that were administered S-oxprcnolol or a placebo.
Figure 13 is a graph showing the change in fat mass per al day alter
ALS onset ol‘mice populations that were administered with S-oxprenolol, S-pindolol, or a
placebo. The asterisk (*) tes that the p value is less than 0.05 versus placebo.
Figure 14 is a graph g the percent survival of mice populations that
were administered with enolol, rilutek, propanolol, oxprenolol (racemic), or R-
oxprenolol. The sample size in the population is indicated by “n.”
Figure 15 is a graph showing the percent survival of male mice populations
that were administered with S-oxprenolol, rilutek, propanolol. oxprenolol (racemic), or R
oxprenolol. The sample size in the population is indicated by “n."
Figure 16 is a graph showing the percent al of female mice populations
that were administered with S-oxprenolol, Iilutek, propanolol, oxprenolol (racemic; or R-
oxprenolol. The sample size in the population is indicated by “n.”
Figure 17 is a graph showing the change in disease progression scored from
score 1 to score 2 of mice populations that were administered with S—oxprenolol, rilutek,
propanolol, oxprenolol icl, or R-oxprenolol.
Figure 18 is a graph g the change in disease progression scored from
score 2 to score 3 of mice populations that were administered with S~oxprenoloh rilutek,
propanolol, oxprenolol (racemic), or enolol.
Figure 19 is a graph showing the change in disease progression scored from
score 1 to score 3 of mice populations that were stered with enolol, rilutek,
propanolol, oxprenolol (racemic), or enoiol.
Figure 20A is a graph showing the change in body weight of mice populations
that were administered with S-oxprcnolol, R-oxprenolo], or rilutck. Figure 208 is a graph
showing the change in body weight of male mice populations that were administered with S—
oxprenolol, R-oxprenolol, or rilutek. Figure 20C is a graph showing the change in body
weight of female mice tions that were administered with S—oxprenolol, R-oxprenolol,
or rilutek. Figure 20D is a graph showing the change in lean mass of mice populations that
were administered with Svoxprenolol, R.~oxprenolol, or rilutelc Figure 20F. is a graph
showing the change in lean mass of male mice populations that were administered with S-
oxprenolol, R-oxprenolol. or k. Figure 20F is a graph showing the change in lean mass
of female mice populations that were stered with S~oxprenolol. R-oxprenolol, or
rilutek. Figure 200 is a graph showing the change in fat mass ofmice populations that were
stered with S-oxprenolol, R-oxprenolol, or rilutek. Figure 20H is a graph showing the
change in fat mass of male mice tions that were stered with S—oxprenolol, R-
oxprenolol, or rilutek. Figure 201 is a graph showing the change in fat mass of female mice
populations that were administered with S-oxprenolol. R-oxprenolol, or rilutek. The sample
size in the population is indicated by “n.”
Figure 2] A is a graph showing the heart mass of mice populations that. were
administered with S-oxprenolol, R—oxprenoloL or rilutek at the end of the study. Figure 21B
is a graph showing the heart mass of male mice tions that were administered with S-
oxprenolol, R-oxprenolol, or rilutek at the end ol‘ the study. Figure 21C is a graph showing
the heart mass of female mice tions that were administered with S-oxprenolol, R-
oxprenolol, or rilutek at the end of the study. Figure 2lD is a graph showing gastrocnemius
muscle weight of mice populations that were administered with S-oxprenolol, R-oxprenolol,
or rilutek at the end ot‘the study. Figure 2113 is a graph showing gastroenemius muscle
weight of male mice populations that were administered with S—oxprenolol. R—oxprenolol, or
rilutek at the end of the study. Figure 21 F is a graph showing gastrocnemius muscle weight
of female mice populations that were administered wilh S-oxprenolol. R-oxprenolol, or
rilutek at the end of the study. Figure 216 is a graph showing tibialis muscle weight of mice
populations that were administered with S—oxprenolol, R~oxprenoloL or rilutek at the end of
the study. Figure 2111 is a graph showing tibialis muscle weight of male mice populations
that were administered with S-oxprenolol, R—oxprenolol, or rilutek at the end of the study.
Figure 211 is a graph showing tihiulis muscle weight of female mice tions that were
administered with S—oxprenolol, R—oxprenolol, or k at the end ol'the study. The sample
size in. the population is indicated by “n.”
ED DESCRIPTION OF THE INVENTION
The present invention provides use of an S—enantiomerically enriched
composition of a beta blocker for achieving beneficial results in individuals having
ophic lateral sclerosis, such as treating ophic lateral sclerosis, prolonging
survival, preventing lean mass loss, improving quality of life, and/or treating muscle wasting.
In an S-enantiomerically enriched composition ot‘a beta blocker or a pharmaceutically
acceptable salt thereof, the beta blocker or a pharmaceutically acceptable salt f has one
chiral center and the composition is enantiomerically enriched for the S~enantiomer. Thus, as
used herein, “S-enantiomerically enriched composition of a beta blocker” refers to a beta
blocker having one chiral center and the composition is cnantiomerically ed for the S-
enantiomer. in some embodiments. the beta r is oxprenolol or a pharmaceutically
acceptable salt thereof.
The present invention is based on the surprising finding that S—oxprenolol
significantly improved survival in animals having amyotrophic lateral sclerosis in an
experiment using an amyotrophic l sclerosis animal model. Other effects of the
compositions were observed on preserving lean body mass and preventing body weight loss
in the animals. At least. these effects suggest that S-oxprenolol is effective in treating
amyotrophic l sis and prolonging al.
Thus, the present invention, in one aspect, provides methods of treating
amyotrophic lateral sclerosis, prolonging survival, preventing lean mass loss, preventing
and/or treating muscle wasting, or improving quality of life in an individual having
amyotrophic lateral sis, comprising administering to the individual an effective amount
ofan S-enantiomerically enriched composition of a beta blocker or a pharmaceutically
acceptable salt thereof. in some embodiments. the beta blocker is oxprenolol or a
pharmaceutically acceptable salt thereof.
|0039l Also provided are kits, unit dosages, medicines, and articles ofinanufacture
that are useful for methods described .
Definitions
The following terms have the following meanings unless otherwise indicated.
Any undefined terms have their ad ized meanings.
] As used herein, “treatment” or “treating” is an approach for obtaining
beneficial or desired results including clinical results. For purposes of this invention,
beneficial or desired clinical results include, but are not limited to. one or more of the
following: alleviating one or more symptoms resulting from the disease, diminishing the
extent of the e, stabilizing the disease (eg, preventing or delaying the ing of the
disease), preventing or ng the spread (cg, metastasis) of the e, preventing or
delayng the recurrence of the disease, delay or slowing the progression of the disease,
ameliorating the disease state, providing a remission al or total) of the disease,
decreasing the dose ofone or more other medications required to treat the disease, delaying
the progression of the disease, increasing the quality oflife, and/or prolonging survival. Also
encompassed by “treatment” is a reduction of ogical uence of amyotrophic
lateral sclerosis. The methods of the invention contemplate any one or more of these aspects
of treatment.
“1042] The term idual” refers to a mammal and includes, but is not limited to,
human, bovine. horse, feline, canine, rodent. or primate. In some embodiments. the
individual is a human.
As used herein, an “at risk” individual is an individual who is at risk of
developing amyotrophic lateral sclerosis. An individual “at risk" may or may not have
detectable disease, and may or may not have displayed detectable disease prior to the
treatment methods described herein. “At risk” denotes that an individual has one or more so
called risk factors, which are measurable parameters that correlate with pment of
amyotrophic lateral sclerosis. An individual having one or more of these risk factors has a
higher probability of developing amyotrophic lateral sclerosis than an individual Without
these risk factorts).
As used herein, “delaying“ the pment of a disease means to defer,
hinder, slow, retard, stabilize, and/or ne development of the e. This delay can be
of varying lengths oftime. ing on the history of the disease and/or individual being
treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect,
ass prevention, in that the individual does not develop the disease. A method that
s” development ol’a disease is a method that reduces probability of disease
development in a given time frame and/or reduces the extent of the disease in a given time
Frame, when compared to not using the method. Such comparisons are typically based on
clinical studies, using a statistically cant number of subjects.
[0045i As used , by “combination therapy" is meant that a first agent be
administered in conjunction with another agent. “In conjunction with” refers to
administration of one treatment modality in addition to another treatment modality, such as
administration of a nanoparticle composition described herein in addition to administration of
the other agent to the same individual. As such, “in conjunction with” rei’e rs to stration
of one treatment modality , . or after delivery of the other treatment modality to
the individual. Such combinations are considered to be part ofa single treatment regimen or
regime.
2014/000274
|0046| The term “effective amount” used herein refers to an amount of a compound
or composition sufficient to treat a ed disorder, condition or disease such as ameliorate,
palliate, lessen. and/or delay one or more of its symptoms. in nce to ophic lateral
sclerosis, an effective amount comprises an amount ent to prevent or delay other
unwanted symptoms associated with amyotrophic lateral sclerosis. in some embodiments, an
effective amount is an amount sufficient to delay development. in some embodiments, an
effective amount is an amount sufficient to prevent or delay ence. An effective amount
can be administered in one or more administrations.
The term “simultaneous administration,” as used herein, means that a first
therapy and second therapy in a combination therapy are administered with a time separation
of no more than about i5 minutes, such as no more than about any of 10, 5, or 1 minutes.
When the first and second therapies are administered simultaneously, the first and second
therapies may be contained in the same ition (ag, a composition comprising both a
first and second therapy) or in separate compositions (cg a first therapy in one ition
and a second therapy is contained in another composition).
As used herein, the term “sequential administration” means that the first
y and second therapy in a combination therapy are administered with a time separation
of more than about [5 minutes, such as more than about any ot‘20. 30, 40, 50, ()0, or more
minutes. Either the first therapy or the second therapy may be administered first. The first and
second therapies are contained in te compositions, which may be contained in the same
or different packages or kits.
[0049! As used herein, the term “concurrent administration” means that the
administration of the first y and that of a second therapy in a combination therapy
p with each other.
As used herein, by “pharmaceutically acceptable“ or “pharmacologically
compatible" is meant a material that is not biologically or otherwise undesirable, sag. , the
material may be incorporated into a ceutical composition administered to an
individual without causing any significant undesirable biologicai effects or interacting in a
deleterious manner with any ol‘the other components ofthe composition in which it is
contained. Pharmaceutically acceptable carriers or excipients have preferably met the
required standards of toxicological and manufacturing testing and/or are included on the
inactive ient Guide prepared by the U.8. Food and Drug administration.
[005” An "adverse event" or “AE’ as used herein refers to any untoward medical
occurrence in an individual receiving a marketed pharmaceutical product or in an individual
who is participating on a clinical trial who is receiving an investigational or non-
investigational pharmaceutical agent
The term “isomers” or “stereoisomers” refers to compounds which have
identical chemical constitution, but differ with regard to the arrangement of the atoms or
groups in space.
The term l” refers to molecules which have the property of non-
superimposability ofthe mirror image partner, while the term “achiral” refers to les
which are superimposable on their mirror image partner,
The term “diastereomers” refers to stereoisomcrs with two or more centers of
metry and whose molecules are not mirror images of one another.
The term “enantiomers” refers to two stereoisomers of a compound which are
non—superimposable mirror images of one r. An equimolar mixture of two
enantiomers is called a “racemic mixture” or a “racemate.”
The term “enantiomerieally enriched" means that the racemic mixture (i.e.,
50/50 e of the enantiorners) has been purified such that one enantiomer comprises
greater than 50% of the total amount of the compound present. For example, a composition
that is enantiomerically ed for S-oxprenolol is a composition wherein more than 50%
of the oxprenolol is the S-enantiomer of oxprenolol (S-oxprenolol).
The degree of enantiomeric ment ot‘a composition can be determined by
“enantiomeric excess,” or ee. “Enantiomeric excess” represents the percentage of one
omer in excess of the other. For instance, a composition having a 75:25 mixture of S—
oxprenolol and R-oxprenolol has a 75 3 50 % ee, while a 50:50 racemic mixture has a 50
— 25
— 50 = 0 % ee. The value ot'ee will be a number from 0 to 100, 0 being c and 100
being pure, single enantiomer.
The term “phannaceutically acceptable salt” means a salt which is acceptahie
for stration to a subject, such as a mammal (salts with counterions having acceptable
mammalian safety for a given dosage regime). Such salts can be derived from
phannaceutically acceptable inorganic or organic bases and from pharniaeeutically
acceptable inorganic or organic acids. “Pharmaceutically acceptable salt" refers to
phannaceutically acceptable salts ot'a compound, which salts are derived from. a variety of
organic and nic COLmter ions well known in the art and include: by way of example
only, sodium. potassium, m. magnesium. ammonium, tetraalkylanunonium, and the
like; and when the molecule contains a basic functionality, salts of organic or inorganic acids,
such as hydrochloride. hydrobromide, formate. te, besylate. mesylate. e. maleate,
oxalate, and the like.
The term “salt thereof” means a compound formed when a proton of an acid is
replaced by a , such as a metal cation or an organic cation and the like. Where
applicable. the salt is a phaimaceutically able salt, although this is not required for salts
of intermediate compounds that are not intended for administration to the subject. By way of
example, salts ofthe present nds include those wherein the compound is protonated
by an inorganic or organic acid to form a cation, with the ate base of the inorganic or
organic acid as the anionic component of the salt.
“Solvate” refers to a complex formed by combination of solvent molecules
with molecules or ions of the solute. The solvent can he an organic compound, an inorganic
compound, or a mixture ofboth. Some examples of solvents include, but are not limited to,
methanol. MN—dimethylformamide, tetrahydrofuran. dimethylsulfoxide, and water. When the
solvent is water. the solvate formed is a hydrate.
it will be iated that the term “or a salt or solvate thereof” is intended to
include all permutations of salts and solvates, such as a solvate ot‘a phannaceutically
acceptable salt ol’a subj eet compound.
[0062[ As used herein, “in conjunction with” refers to administration of one treatment
modality in addition to another treatment modality. As such, “in conjunction with” refers to
administration of one treatment modality before, during or after administration of the other
treatment modality to the individual.
As used herein and in the appended claims, the singular forms “a,” “an," and
“the” e plural reference unless the context clearly indicates otherwise.
[0064[ Reference to “about" a value or parameter herein includes (and describes)
ments that are directed to that value or parameter per se. For example, ption
referring to “about X” includes description of “X.”
It is understood that aspects and variations of the invention described herein
include sting” and/or sting essentially 0t” aspects and variations.
Methods of the present invention
The present disclosure, in one aspect, provides methods of treating
amyotrophic lateral sclerosis. In some embodiments, there is provided a method of treating
amyotrophic lateral sclerosis in an individual having amyotrophic lateral sclerosis,
comprising administering to the dual an effective amount of an S-enantiomerically
enriched composition of a beta blocker or a pharmaceutically acceptable salt thereof (such as
a composition having at least about any one of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%,
90%, 95%, 96%, 97%, 98%, 99%, or 99.9% ce). In some embodiments. the beta blocker is
selected from the group consisting of acebutolol. atenolol, betaxolol. bisoprolol, carteolol.
celeprolol, lol, metoprolol, nadolol, nebivolol, oxprenolol, penbutolol, ol.
propanolol, sotalol, esmolol, carvedilol, timolol, bopindolol, medroxalol, bucindolol.
levobunolol, metipranolol, celiprolol and enone or a pharmaceutically acceptable salt
thereof. In some embodiments, the beta blocker is oxprenolol or a pharmaceutically
acceptable salt thereof. In some embodiments, the composition ses an enantiomeric
excess of at least about 10% (such as at least about any one ot‘20%, 3t %, 40%, 50%, 60%,
70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.9%) of S-oxprenolol. In some
embodiments, there is provided a method ot‘treating amyotrophie lateral sclerosis in an
individual having amyotrophic l sclerosis, comprising administering to the individual an
ett‘ective amount of a composition comprising oxprenolol or a pharmaceutically acceptable
salt thereof, wherein the composition comprises an omeric excess of at least. about 99%
(for example at least about 99.9%) of enolol. In some embodiments, there is provided
a method ting amyotrophic lateral sclerosis in an individual having ophic lateral
sclerosis. comprising administering (such as orally administering) to the individual an
effective amount of a composition comprising oxprcnolol or a pharmaceutically acceptable
salt thereof, wherein the composition is enantiomerically enriched for S—oxprenolol. (for
example comprises an enantiomeric excess of at least about 99% of S-oxprenolol), wherein
the amount of S—oxprenolol in the composition is about 50 mg to about 160 mg (such as
about 80 to about 160 mg, for example about l00 mg to about 160 mg).
In some embodiments, there is ed a method of prolonging survival ofan
individual having amyotrophic l sclerosis, comprising administering to the individual an
effective amount of an tiomcrically enriched composition ofa beta blocker or a
pharmaceutically acceptable salt f (such as a composition having at least about any one
of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.9%
ee). in some embodiments, the beta blocker is selected from the group consisting of
acebutolol, atenolol, betaxolol, bisoprolol, carteolol, celeprolol, lol. metoprolol.
nadolol, ncbivolol, oxprenolol, penbutolol, pindolol, propanolol, sotalol, esmolol, carvedilol,
timolol, bopindolol, medroxalol, dolol, levobunolol, metipranolol, eeliprolol and
propafenone. in some ments, the beta blocker is olol or a phannaceutieally
acceptable salt thereof. In some embodiments, the composition comprises an enautiomeric
excess of at least about 10% (such as at least about any one of 20%, 30%, 40%, 50%, 60%,
70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%. or 99.9%) ol’S~oxprenololi in some
embodiments, there is ed a method of prolonging survival in an individual having
amyotrophic lateral sclerosis, comprising administering to the individual an effective amount
of a composition comprising oxprenolol or a pharmaceutically acceptable salt thereof,
wherein the ition comprises an enantiomeric excess of at least about 99% (for
example at least about 99.9%) ofS—oxprenolol. in some embodiments, there is provided a
method of prolonging survival of an individual having ophic lateral sclerosis,
comprising administering (such as orally stering) to the dual an effective amount
ofa composition comprising oxprenolol or a pharmaceutically acceptable salt thereof,
wherein the composition is enantiomerically enriched for S~oxprenolol (for example
comprises an enantiomeric excess of at least about 99% of enolol), wherein the amount
of S-oxprenolol in the composition is about 50 mg to about 160 mg (such as about 80 to
about 160 mg, for example about 100 mg to about 160 mg). In some embodiments. the
method prolongs the survival ol’the individual by at least any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
ll, 12, 18, or 24 months.
In some embodiments, there is provided a method of prolonging progression-
free survival in an individual with amyotrophic lateral sclerosis, comprising administering to
the dual an effective amount of an S-enantiomerically enriched composition of a beta
blocker or a pharmaceutically acceptable salt thereof (such as a ition having at least
about any one of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%,
99%, or 99.9% co). in some embodiments, the beta blocker is ed from the group
consisting of aeebutolol, atenolol. betaxolol, bisoprolol, catteolol, celeprolol, labetalol,
metoprolul, nadolol, nebivolol, oxprenolol, olol, pindolol, propanolol, sotalol, esmolol,
caivedilol, timolol, bopindolol, mcdroxalol, bucindolol, lcvobunolol. metipranolol, olol
and propafenone. in some embodiments. the beta blocker is oxprenolol or a pharmaceutically
acceptable salt thereof. In some embodiments, the composition comprises an enantiomeric
excess of at least about 10% (such as at least about any one of20%, 30%, 40%, 50%, 60%,
70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.9%) ol‘S-oxprenolol. In some
embodiments, there is provided a method of prolonging progression-tree survival in an
individual with ophic lateral sclerosis, sing administering to the individual an
effective amount ofa composition comprising oxprenolol or a pharmaceutical ly acceptable
salt thereof, wherein the ition ses an enantiomeric excess of at least about 99%
(for example at least about 99.9%) of S-oxprenolol. In some embodiments, there is provided
a method ot‘pt‘olonging progression—free suwival in an individual with amyotrophic lateral
sclerosis. comprising administering (such as orally administering) to the individual an
eftective amount ot‘a composition comprising oxprenolol or a pharmaceutically able
salt thereof, wherein the composition is enantiomerically enriched for S—oxprenolol (for
e ses an enantiomeric excess of at least about 9 % of S-oxprenolol), wherein
the amount of S-oxprenolol in the composition is about 50 mg to about 160 mg (such as
about 80 to about 160 mg, for example about l00 mg to about 160 mg).
In some embodiments, there is provided a method of alleviating one or more
symptoms associated with amyotrophic lateral sclerosis. sing administering to the
individual an tive amount of an S~enantiomerically enriched composition of a beta
blocker or a pharmaceutically acceptable salt thereof (such as a composition having at least
about any one of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%. 95%, 96%, 97%, 98%,
99%, or 99.9% ee). In some embodiments, the beta blocker is selected from the group
consisting of acebutolol, atenolol, betaxolol, bisoprolol, carteolol, celeprolol, labetalol,
metoprolol, nadolol, nebivolol, oxprenolol, olol, pindolol, propanolol, sotalol, esmolol,
carvedilol, timolol, bopindolol. medroxalol. bucindolol, levobunolol, metipranolol, olol
and propalenone. ln some embodiments, the beta blocker is oxprenolol or a pharmaceutically
acceptable salt thereof. In some embodiments. the composition comprises an omeric
excess of at least about 10% (such as at least about any one 0f20%, 30%, 40%, 50%, 60%,
70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%. or 99.9%) of S—oxprenolol. In some
embodiments, there is provided a method ofalleviating one or more symptoms associated
with atnyotrophic lateral sclerosis, comprising stering to the individual an effective
amount of a composition comprising oxprenolol or a pharmaceutically acceptable salt
thereof, wherein the composition comprises an enantiomeric excess of at least about 99% (for
example at least about 99.9%) of S—oxprenolol. In some embodiments, there is provided a
method of alleviating one or more symptoms associated with amyotrophic lateral sclerosis,
comprising administering (such as orally administering) to the individual an ive amount
of a composition comprising oxprenolol or a pharmaceutically acceptable salt thereof,
wherein the composition is enantiomerically enriched for S-oxprenolol (for example
comprises an enantiomeric excess ofat least about 99% ol’S—oxprenolol), wherein the amount
of S—oxprenolol in the composition is about 50 mg to about 160 mg (such as about 80 to
about 160 mg, for example about 100 mg to about 160 mg).
in some embodiments, there is provided a method of delaying the
development otrophic lateral sclerosis in an individual having amy‘otrophic lateral
sclerosis. comprising administering to the individual an effective amount ofan S—
enantinmerically enriched composition ot'a beta blocker or a pharmaceutical ly acceptable salt
thereof (such as a composition having at least about any one of l0%, 20%. 30%, 40%, 50%,
60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%. 99%, or 99.9% ee). in some embodiments, the
beta blocker is oxprenolol or a pharmaceutically acceptable salt thereof. In some
embodiments, the beta blocker is selected from the group consisting utolol, atenolol,
betaxolol, bisoprolol, carteolol, olol, labetalol, metoprolol, nadolol, nebivolol,
oxprenolol, penbutolol, pindolol, propanolol. sotalol, esmolol, ilol, timolol, bopindolol,
medroxalol, olol, levobunolol, metipranolol, celiprolol and propafenone. in some
embodiments, the ition comprises oxprenolol or a phannaceutically acceptable salt
thereof. In some embodiments, the composition comprises oxprenolol or a pharmaceutically
acceptable salt thereof, wherein the ition is enantiomerically enriched for S~
oxprenolol. in some embodiments, the ition comprises an enantiomeric excess of at
least about 10% (such as at least about any one of 20%, 30%, 40%, 50%, 60%, 70%, 80%,
90%, 95%, 96%, 97%, 98%, 99%, or 99.9%) of S—oxprenolol. in some ments, there is
provided a method aying the development of amyotrophic lateral sclerosis in. an
individual having amyotrophic lateral sclerosis, comprising administering to the individual an
effective amount of a composition comprising oxprcnolol or a pharmaceutically acceptable
salt f, wherein the composition comprises an enantiomeric excess of at least about 99%
(for example at least about 99.9%) of S-oxprenolol. In some embodiments, there is ed
a method ot‘delaying the development of atnyotrophic lateral sclerosis in an individual
having amyotrophic lateral sis, comprising administering (such as orally administering)
to the individual an effective amount of a composition comprising oxprenolol or a
pharmaceutically acceptable salt thereof, wherein. the composition is enantiomerically
enriched for S—oxprenolol (for example ses an enantiomeric excess of at least about
99% of S-oxprenolol), wherein the amount of S~oxprenolol in the composition is about 50 mg
to about 160 mg (such as about 80 to about 160 mg, for example about 100 mg to about l60
mg). In some embodiments, the method prolongs the survival of the individual by at least
any of 1. 2, 3, 4, 5, 6, 7, 8,9, 10,11, 12,18, or 24 months.
|007ll ln some embodiments, there is provided a method ofpreventing loss of lean
body mass in an dual having amyotrophic lateral sclerosis, comprising administering to
the individual an effective amount of an S-enantiomerically enriched composition of a beta
blocker or a pharmaceutically acceptable salt f (such as a composition having at least
about any one of l0%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%,
99%, or 999% cc). In some embodiments, there is provided a method of ng loss of lean
body mass in an individual having amyotrophic lateral sclerosis, comprising administering to
the dual an effective amount of an S-enantiomerically enriched composition ot‘a beta
blocker or a pharmaceutically acceptable salt thereof (such as a composition having at least
about any one of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%. 98%,
99%, or 99.9% eye). In some embodiments, the method of treating loss of lean body mass is
reversing muscle wasting or sing muscle weight. In some ments, the beta
blocker is selected from the group consisting of acebutolol, atenolol, betaxolol, bisoprolol,
carteolol, celeprolol, labetalol, metoprolol, nadolol, nebivolol, oxprenolol, penbutolol,
pindolol, propanolol, sotalol, l, carvedilol, timolol, bopindolol, medroxalol,
bucindolol, levobunolol, metipranolol, celiprolol and enone. ln some embodiments,
the beta blocker is oxprenolol or a phannaceutically acceptable salt thereof. ln some
embodiments, the composition comprises an enantiomeric excess of at least about 10% (such
as at least about any one of 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%.
98%, 99%, or 99.9%) ofS—oxprenolol. ln some embodiments, there is provided a method of
preventing loss of lean body mass in an individual having amyotrophic lateral sclerosis.
comprising administering to the individual an effective amount of a ition comprising
oxprenolol or a ceutically acceptable salt thereof, wherein the composition comprises
an enantiomeric excess of at least about 99% (for example at least about 99.9%) of S-
oxprenolol. in some embodiments, there is provided a method of preventing loss of lean
body mass in an individual having amyotrophic lateral sclerosis, comprising administering
(such as orally administering) to the individual an effective amount ot‘a composition
comprising oxprenolol or a pharmaceutically acceptable salt thereof, n the composition
2014/000274
is enantiomerically enriched for S—oxprenolol (for example comprises an enantiomeric excess
of at least about 99% of S—oxprenolol), wherein the amount of S—oxprenolol in the
ition is about 50 mg to about l60 mg (such as about 80 to about 160 mg, for example
about 100 mg to about 160 mg). In some embodiments, the loss oflcan body mass of the
individual is no more than about 10% (for example no more than about any of 10%, 9%, 8%,
7%, 6%, or 5%) of the total lean body mass. in some embodiments, the loss of lean body
mass is evaluated over a time period of about 1 month to 2 years (for example, about 1, 2, 3,
4, 5, 6, 7, 8, 910,11. 12,13, 14,15,16, l7, 20 or 24 months).
, 21, 22, 23,
In some embodiments, there is provided a method of treating muscle wasting
in an individual having amyotrophic lateral sclerosis, sing stering to the
individual an. effective amount of an S—enantiomcrically enriched composition ofa beta
blocker or a pharmaceutically able salt thereof (such as a composition having at least
about any one of 10%. 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%,
99%, or 99.9% cc). In some embodiments. the beta blocker is selected from the group
consisting ofacebutolol, atenolol. betaxolol, bisoprolol, carteolol, olol, labetalol,
olol, nadolol, nebivolol, oxprenolol, penbutolol, pindolol, propanolol, sotalol, esmolol,
carvedilol, timolol, bopindolol, alol, bucindolol, levobunolol, metipranolol, celiprolol
and propafenone. In some embodiments, the beta blocker is oxprenolol or a phamtaceutieally
acceptable salt thereof. In some embodiments, the composition comprises an enantiomeric
excess of at least about 10% (such as at least about any one of 20%, 30%, 40%, 50%, 60%,
70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.9%) of S~oxprenolol. In some
ments, there is provided a method ot‘treating muscle wasting in an individual having
amyotrophic lateral sclerosis, comprising administering to the individual an effective amount
of a composition comprising oxprenolol or a pharmaceutically acceptable salt thereof,
wherein the composition comprises an enantiomeric excess of at least about 99% (for
example at least about 99.9%) of S—oxprenolol. In some embodiments, there is provided a
method of treating muscle wasting in an individual having amyotrophic lateral sclerosis,
comprising administering (such as orally administering) to the individual an effective amount
of a composition comprising oxprenolol or a pharmaceutically acceptable salt thereof,
wherein the composition is omerically enriched for S—oxptenolol (for example
comprises an orneric excess of at least about 99% of S—oxprenolol), wherein the amount
of Svoxprenolol in the compositi on is about 50 mg to about 160 mg (such as about 80 to
about 160 mg, For e about 100 mg to about 160 mg). In some embodiments. the
2014/000274
muscle wasting of the individual is no more than about 10% (for e no more than about
any of 10%, 9%, 8%, 7%, 6%, or 5%) of the total body weight. In some embodiments, the
muscle wasting is evaluated over a time period of about 1 month to 2 years (for example,
about 1,2, 3,4, 5, 6,7, 8, 9,10,11,12,13,14,15,16,17,18,19 ,20 or24
, 21, 22,23,
months). In some embodiments. the method leads to a reduction of muscle wasting, i.e., a
slow-down ol‘musele loss in the individual. ln some embodiments, the method leads to a
reversal of muscle g, i.e., an increase in muscle weight in the individual.
in some embodiments, there is provided a method of improving y of life
of an individual having amyotrophic lateral sclerosis, comprising administering to the
individual an effective amount of an S-enantiomerically enriched composition ofa beta
blocker or a pharmaceutical 1y acceptable salt thereof (such as a composition. having at least
about any one of 10%, 20%. 30%, 4 %, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%.
99%, or 99.9% ea). In some embodiments, the beta blocker is selected from the group
consisting of acebutolol, ol, betaxolol, bisoprolol, lol, celeprolol, labetalol,
nietoprolol, nadolol, nebivolol, oxprenolol, olol, pindolol, propanolol, sotalol, esmolol,
carvedilol, timolol, bopindolol, medroxalol, bucindolol, levobunolol, metipranolol, celiprolol
and propafenone. in some embodiments, the beta r is olol or a pharmaceutically
acceptable salt thereof. in some embodiments. the composition comprises an enantiomeric
excess of at least about 10% (such as at least about any one of 20%, 30%, 40%, 50%, 60%,
70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.9%) of S—oxprenolol. In some
embodiments, there is provided a method of improving quality of life of an individual having
amyotrophic lateral sclerosis, comprising administering to the individual an effective amount
of a composition sing oxprenolol or a pharmaceutically acceptable salt thereof,
n the composition comprises an enantiomeric excess ol’at least about 9.9% (for
example at least about 99.9%) of S-oxprenolol. In. some embodiments, there is provided a
method of improving quality of life ofan individual having amyotrophic lateral sclerosis,
comprising administering (such as orally stering) to the individual an effective amount
of a composition comprising oxprenolol or a. pharmaceutically able salt thereof,
n the composition is enantiomerieally enriched for S-oxprenolol (for example
comprises an enantiomeric excess of at least about 99% ofS-oxprenolol), wherein the amount
of S—oxprenolol in the composition is about 50 mg to about 160 mg (such as about 80 to
about 160 mg, for example about 100 mg to about l60 mg). improvement of'quality of life
can be assessed, for example, by food intake, locomotive activity, improvement in fatigue or
dyspnea or global patient assessment scores. in short physical performance battery scores, in
standard clinical assessment of functional performance, muscle strength, gait speed, leg
strength and hand grip th. 6-minute corridor walk test. stair climbing power, ability to
tolerate courses of chemotherapy and other tests or instruments or questionnaires assessing
patient quality oflife.
“1074] ln some embodiments, there is provided a method of increasing food intake of
an individual having amyotrophic lateral sclerosis. comprising stering to the individual
an effective amount of an S-enantiomerically enriched composition of a beta blocker or a
phannaceutically acceptable salt: thereof (such as a, composition having at least: about any one
of l0%, 20%, 30%, 40%. 50%, 60%, 70%= 80%, 90%, 9 %, 96%., 97%, 98%” 999/ or 99.9%
cc). In some embodiments, the beta blocker is selected from the group consisting of
olol, atenolol, betaxolol. olol, carteolol. oiol, labetalol, metoprolol,
nadolol, nebivolol, oxprenolol, penbutolol, pindolol, propanolol, sotalol, esmolol, carvcdilol,
timolol, bopindolol, mcdroxaloL bucindolol, levobunolol, anolol, celiprolol and
propafenone. in some embodiments, the beta blocker is oxprenolol or a pharmaceutically
able salt thereof. In some embodiments, the composition ses an enantiomeric
excess of at least about 10% (such as at least about any one of 20%, 30%, 40%, 50%, 60%,
70%. 80%, 90%, 95%, 96%, 97%, 98%. 9.9%, or 99.9%) ofS—oxprenolol. in some
embodiments, there is provided a method of sing food intake of an individual having
amyotrophic lateral sclerosis, comprising stering to the dual an effective amount
ol'a composition comprising oxprenolol or a pharmaceutically acceptable salt thereof,
wherein the composition comprises an enantiomeric excess of at least about 99% (for
example at least about 99.9%) of S—oxprenolol. In some embodiments, there is provided a
method of increasing food intake of an individual having amyotrophic lateral sclerosis,
comprising stering (such. as orally administering) to the individual an effective amount
ofa composition comprising oxprenolol. or a pharmaceutically acceptable salt thereof,
wherein the composition is enantiomerically enriched for cnolol (for example
comprises an enantiomeric excess of at least about 99% of enolol), wherein the amount
of S-oxprenolol in the composition is about 50 mg to about 160 mg (such as about 80 to
about 160 mg, for e about 100 mg to about 160 mg).
In some embodiments, there is provided a method of increasing locomotive
activity of an individual having amyotrophic lateral sclerosis, comprising administering to the
individual an ive amount of an S-enantiomerically enriched composition ofa beta
WO 38814
blocker or a pharmaceutically acceptable salt f (such as a composition having at least
about any one of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%,
99%, or 99.9% ee). In some embodiments, the beta blocker is selected from the group
consisting ot‘acebutolol, atenolol, betaxolol, bisoprolol, carteolol, celeprolol, labetalol,
metoprolol, nadolol, nebivolol, oxprenolol, penbutolol. pindolol, propanolol, sotalol, esmoloi,
carvedilol, timoiol, hopindolol, medroxalol, bucindolo], levobm‘nolol, metipranolol, celiprolol
and propafenone. In some embodiments, the beta blocker is oxprenolol or a pharmaceutically
acceptable salt thereof. In some embodiments, the composition comprises an enantiomerie
excess of at least about 10% (such as at least. about any one of 20%, 30%, 40%, 50%, 60%.
70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.9%) ofS—oxprenolol. in some
embodiments, there is provided a method of increasing locomotive activity of an individual
having amyotrophic lateral sclerosis, comprising administering to the individual an ive
amount of a composition comprising oxprenolol or a pharmaceutically able salt
thereof, wherein the composition comprises an omeric excess of at least about 99% (for
example at least about 99.9%) of enolol. ln some embodiments, there is provided a
method of increasing locomotive activity of an individual having amyotrophic lateral
sclerosis, comprising administering (such as orally administering) to the individual an
effective amount of a composition comprising oxprenolol or a pharmaceutically acceptable
salt f, wherein the ition is enantiomerically ed for S-oxprenoloi (for
example comprises an enantiomeric excess of at least about 99% of S—oxprenolol), wherein
the amount ol‘S—oxprenolol in the composition is about 50 mg to about 160 mg (such as
about 80 to about 160 mg, for example about 100 mg to about 160 mg).
ln some embodiments, there is provided a method of improving fatigue or
dyspnea in an individual having amyotrophic lateral sclerosis, comprising stering to
the individual an effective amount: of an S-enantiomerically ed composition ol‘a beta
blocker or a pharmaceutically acceptable salt thereof (such as a composition having at least
about any one of l 0%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%,
99%, or 99.9% ee). In some embodiments, the beta. blocker is selected from the group
consisting ol’acebutolol, atenolol, lol, bisoprolol, carteolol, celeprolol, labetalol,
metoprolol, l, nebivolol, oxprenolol, olol, pindolol, propanolol, sotalol. esmolol.
ilol, timolol, bopindolol, medroxalol, hucindolol, levobunolol, metipranolol, celiprolol
and propatenone. In some embodiments, the beta blocker is oxprenolol or a pharmaceutically
acceptable salt thereof. In some embodiments, the composition comprises an enantiomeric
excess of at least about 10% (such as at least about any one of 20%, 30%, 40%, 50%, 60%,
70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.9%) of enolol. In some
embodiments, there is provided a method ofimproving fatigue or dyspnea in an individual
having amyotrophic lateral sclerosis, comprising administering to the individual an cfi'ective
amount of a composition comprising oxprenolol or a pharmaee‘utically acceptable salt
thereof, wherein the composition comprises an meric excess of at least about 99% (for
e at least about 99.9%) of S—oxprenolol. in some embodiments, there is ed a
method of improving fatigue or dyspnea in an individual having amyotrophic lateral
sis, comprising administering (such as orally administering.) to the individual an
effective amount of a composition comprising oxprenolol or a ceutically acceptable
salt thereof, wherein the composition is enantiomerically enriched for S-oxprenolol (for
example comprises an enantiorneric excess of at least about 99% of S—oxprenolol), wherein
the amount ofS—oxprenolol in the composition is about 50 mg to about 160 mg (such as
about 80 to about 160 mg, for example about 100 mg to about 160 mg).
lo some embodiments, there is provided a method of preventing body weight
loss of an individual having amyotrophic- lateral sclerosis, comprising stering to the
individual an effective amount of an S—cnantiomerically enriched composition of a beta
blocker or a pharmaceutically acceptable salt thereot‘(such as a composition having at least
about any one of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%. 96%, 97%, 98%,
99%, or 99.9% ea). In some embodiments, the beta r is selected from the group
consisting ol‘acebutolol, atenolol, betaxolol, bisoprolol, carteolol, eeleprolol, labetalol,
metoprolol, l, nebivolol, oxprenolol, penbutolol, pindolol, olol, sotalol, l,
dilol, timolol, bopindolol, medroxalol, bucindolol, levobunolol, anolol, celiprolol
and enone, In some embodiments, the beta blocker is oxprenolol or a pharmaceutically
acceptable salt thereof. ln some embodiments, the composition comprises an enantiomeric
excess of at least about 10% (such as at least about any one 012096. 30%, 40%, 50%, 60%.
70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.9%) of S—oxprenolol. In some
embodiments, there is provided a method ofpreventing body weightless in an individual
having amyotrophic lateral sclerosis, comprising administering to the individual an effective
amount of a composition comprising oxprenolol or a pharmaceutically acceptable salt:
thereof, wherein the composition comprises an enantiomeric excess of at least about 99% (for
example at least about 99.9%) of S~oxprenoloL In some embodiments, there is ed a
method 01‘ preventing body weight loss clan individual having amyotrophic lateral sclerosis,
comprising administering (such as orally administering) to the individual an effective amount
of a composition comprising oxprenolol or a pharmaceutically acceptable salt thereof,
wherein the composition is enantiomerically enriched for S—oxprenolol (for example
comprises an enantiomeric excess of at least about 99% ot'S-oxprenolol), wherein the amount
of S~oxprenolol in the composition is about 50 mg to about 160 mg (such as about 80 to
about 160 mg, For example about 100 mg to about 160 mg). In some embodiments, the body
weight loss of the individual is no more than about 20% (for example no more than about any
of 15%, 14%, 13%, 12%. 11%, 10%, 9%, 8%, 7%, 6%, or 5%) ofthe total body weight. In
seine embodiments, the body weight loss is ted over a time period of about 1 month to
2 years (for example, about 1, 2, 3, 4, 5, 6, 7, 8,9. 10,11, 12,13,14, 15,16,17,18,19 20
, _.
21, 22, 23, or 24 months).
in some embodiments, there is provided a method of ting loss of body
fat in an individual having amyotrophic lateral sclerosis, comprising administering to the
dual an effective amount of an S-enantiomerically enriched composition of a beta
blocker or a pharmaceutically acceptable salt thereof (such as a composition having at least
about any one of10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 9 %,
99%, or 99.9% ee). In some embodiments, the beta blocker is selected from the group
consisting of olol, atenolol, betaxolol. bisoprolol, carteolol, celeprolol, labetalol,
metoprolol, nadolol, nebivolol, oxprenolol, olol, pindolol, propanolol. sotalol, esmolol,
carvedilol, timolol, bopindolol, medroxalol, bueindolol, levobunolol, anolol. celiprolol
and propal‘enone. In some embodiments, the beta blocker is oxprenolol or a phannaceutically
acceptable salt thereof. In some embodiments, the composition comprises an enantiomeric
excess of at least about 10% (such as at least about any one of 20%, 30%, 40%, 50%, 60%,
70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%. or 99.9%,)01‘S-oxprenolol. In some
embodiments, there is provided a method of ting loss ol'body lat in an individual
having rophie lateral sclerosis, comprising administering to the individual an effective
amount ot‘a composition comprising oxprenolol or a ceutically acceptable salt
thereof, wherein the composition comprises an enantiomeric excess of at least about 99% (for
example at least about 99.9%) of S-oxprenolol. in some embodiments, there is provided a
method of ting loss of body fat in an individual having amyotrophic lateral sclerosis,
comprising administering (such as orally administering) to the individual an effective amount
ot‘a composition comprising oxprenolol or a pharmaceutically able salt thereof,
wherein the composition is omerically enriched for cnolol (for example
comprises an enantiomeric excess of at least about 99% of S—oxprenolol), wherein the amount
of S—oxprenolol in the composition is about 50 mg to about 160 mg (such as about 80 to
about 160 mg, for example about 100 mg to about 160 mg). In some embodiments, the loss
ofbody fat of the individual is no more than about 10% (for example no more than about any
of 15%, 14%, 13%. 12%, 11%. 10%, 9%, 8%, 7%, 6%, or 5%) of the total body fat. In some
embodiments, the loss 01‘ body fat is evaluated over a time period of about l month to 2 years
(for example. about I, 2. 3. 4, 5, 6, 7, 8, 9,10,11,12,13,l4,15,16.17,18,19 20
, . 21, 22,
23, or 24 months).
In some ments, there is provided a method of providing
cardioprotective effects in an dual having amyotrophic lateral sclerosis, comprising
administering to the individual an effective amount of an S-enantiomerically enriched
composition ofa beta blocker or a ceutically acceptable salt thereof (such as a
composition having at least about any one of 10%, 20%, 30%, 40%, 50%, 60%, 70%. 80%,
90%, 95%, 96%, 97%, 98%, 99%, or 99.9% ee). In some embodiments, there is ed a
method of preventing wasting ofa heart muscle in an individual having arnyotrophic l
sclerosis, comprising administering to the individual an effective amount ofan S—
enantiomerically enriched composition of a beta blocker or a pharmaceutically acceptable salt
ft such as a composition having at least about any one of 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, 90%, 95%, 96%. 97%, 98%, 99%, or 999% cc). In some embodiments, the
beta blocker is selected from the group consisting of acebutolol, atenolo], betaxolol,
bisoprolol, carteolol. celeprolol. lol, metoprolol, nadolol, nebivoloi. olol,
penbutolol, pindolol. propanolol, sotalol, esmolol, carvedilol, timolol, bopindolol.
medroxalol, bucindolol, levobunolol, metipranolol, celiprolol and propafenone. In some
embodiments, the beta blocker is oxprenolol or a phannaceutically acceptable salt thereof. In
some embodiments, the composition comprises an enantiomeric excess of at least about 10%
(such as at least about any one of 20%. 30%, 40%, 50%, 60%, 70%, 80%. 90%, 95%. 96%,
97%, 98%, 99%, or 99.9%) ot‘S-oxprenolol. In some embodiments, there is provided a
method of providing cardioprotective effects in an individual having amyotrophic lateral
sclerosis, sing administering to the dual an effective amount of a composition
comprising olol or a pharmaceuticall y able salt thereof, wherein the composition
comprises an enantiomeric excess of at least about 99% (for example at least about 99.9%) of
S~oxprenolol. In some embodiments, there is provided a method of preventing wasting ofa
heart muscle in an individual having ophic lateral sclerosis, comprising administering
2014/000274
to the individual an effective amount of a composition comprising oxprenolol or a
phartnaceutically acceptable salt thereof, wherein the composition comprises an enantiomeric
excess of at least about 99% (for example at least about 99.9%) of S-oxprenolol. In some
embodiments, there is provided a method of providing cardioprotective effects in an
individual having amyot‘rophic lateral sclerosis, comprising administering (such as orally
administering) to the individual an effective amount of a composition comprising oxprenolol
or a pharmaceutically acceptable salt thereof, wherein the composition is enantiotnerically
enriched for S-oxprenolol (for e comprises an enantiomeric excess of at least about
99% ofS—oxprenolol), wherein the amount ol'S—oxprenolol in the composition is about 50 mg
to about l60 mg (such as about 80 to about 160 mg, for example about lOO mg to about 160
mg). In some embodiments, there is provided a method of preventing g ofa heart
muscle in an individual having amyotrophic lateral sclerosis, comprising stering (such
as orally administering) to the individual an effective amount of a ition comprising
oxprenolol or a pharmaceutically acceptable salt thereof, wherein the composition is
enantiomerically enriched for S-oxprenolol (for example comprises an enantiomeric excess of
at least about 99% of S-oxprenolol), wherein the amount of S—oxprenolol in the composition
is about 50 mg to about 160 mg (such as about 80 to about l60 mg. for example about 100
mg to about l60 mg). Cardioprotective effects include one or more of the following:
preventing and treating atrial fibrillation and ventricular fibrillation. improving arrhythmias,
improving diastolic function of :1 hearts and preventing and treating fibrosis of a heart. The
methods described herein are ore useful for any one or more of these cardioprotective
effects.
In some embodiments, there is provided a method ot'preventing sudden death
and/or cardiovascular death in an individual having amyotrophic lateral sis, sing
stering to the individual an effective amount ol'an S-enantiomerically enriched
composition of a beta blocker or a phartnaceutically acceptable salt f (such as a
composition having at least about, any one of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%,
90%, 95%, 96%, 97%, 98%, 99%” or 99.9% ee). In some embodiments. the beta r is
selected from the group consisting utolol, atenolol, betaxolol, bisoprolol, carteolol,
celeprolol, labelalol, olol, nadolol, nebivolol, oxpt‘enolol, pcnbutolol, pindolol,
propanolol, sotalol, esmolol, carvedilol, timolol, bopindolol, medroxalol, bucindolol,
levobunolol, metipranolol, celiprolol and fenone. in some embodiments, the beta
r is oxprcnolol or a phamiaceutically acceptable salt thereof. in some embodiments,
the composition comprises an enantiomeric excess of at least about 10% (such as at least
about any one of20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%,
or 99.9%) of S—oxprenolol. In some embodiments, there is ed a method of preventing
sudden death and/or cardiovascular death in an individual. having amyotrophic l
sclerosis. comprising administering to the individual an effective amount oi’a composition
comprising olol or a phamiaceutically acceptable salt thereof, wherein the composition
comprises an enantiomeric excess of at least about 99% (for example at least about 99.9%) of
S—oxprenolol. in some embodiments, there is provided a method of preventing sudden death
and/or cardiovascular death in an individual having amyotrophic lateral sclerosis, sing
administering (such as orally administering) to the individual an effective amount ofa
composition comprising oxprcnolol or a pharmaceutically acceptable salt thereof, wherein the
composition is enantiomerically enriched for S-oxprenolol (for example comprises an
omeric excess of at least about 99% of enolol). wherein the amount ot‘S—
oxprenolol in the ition is about 50 mg to about 160 mg (such as about 80 to about 160
mg. for example about 100 mg to about 160 mg).
The methods described herein may also be useful for any one or more of the
following: 1) preventing loss of skeletal muscle associated with amyotrophic lateral sclerosis;
2) treating muscle weakness associated with amyotrophic lateral sclerosis; 3) strengthening
skeletal muscle in an individual having ophic lateral sclerosis; 4) treatment ol‘muscle
wasting associated with amyotrophic lateral sclerosis; 5) treating dyspnea associated with
muscle changes in amyotrophic lateral sclerosis; and 6) ing fatigue resistance of
muscle in amyotrophic lateral sclerosis. Skeletal muscle includes, but is not limited to,
gastrocnemius muscle, is , soleus muscle, and extensor digitorum longus (EDL)
muscle. quadriceps. hamstrings. al muscles. hand muscles. triceps, biceps, masseter and
otherjaw muscles, and ostal and other respiratory muscles. The present application
encompasses any of these methods.
in some embodiments. the individual has been diagnosed with or is suspected
of having ophic lateral sclerosis. in some ments, the individual exhibits one or
more symptoms associated with amyotrophic lateral sclerosis. in some embodiments, the
individual is a human. in some embodiments, the individual is at. least: about any of35: 40,
45. 50, 55, 60., 65, 70. 75, 80, or 85 years old. In some embodiments, the individual is a
male. In some embodiments, the individual is a female. In some embodiments. the individual
has been previously d for amyotrophic lateral sclerosis. In some embodiments, the
individual has not previously been treated for rophic lateral sis.
Amyotrophic lateral sclerosis covers a spectrum of egenerative
syndromes characterized by progressive muscular paralysis reflecting degeneration of motor
neurons in the brain and spinal cord. It is a debilitating disease with varied etiology
characterized by rapidly progressive weakness, muscle y and culations, muscle
city, difficulty speaking (dysarthria), lty swallowing (dysphagia). and difficulty
ing (dyspnea).
Amyotrophic l sclerosis can be diagnosed by observation of symptoms
and signs. An individual may receive neurologic examinations at regular intervals to see
whether symptoms are getting worse. Symptoms may include muscle weakness, muscle
atrophy. hyperrellexia (overactive reflexes. including twitching and spastic movement), and
spasticity (tightening and ction of muscles, muscle stiffening). Tests can be run to
obtain definitive information to diagnose ALS or rule out es other than ALS. Such
tests include electromyography (EMG), nerve conduction velocity (NCV) test. magnetic
resonance imaging (MRI), spinal tap, x-rays, myelogram ofthe cervical spine, and muscle
and/or nerve biopsy.
ln some embodiments, the individual has early stage amyotrophic lateral
sclerosis. In some embodiments, the individual has middle stage amyotrophic lateral
sclerosis. In some embodiments, the individual has late stage amyotrophie lateral sclerosis.
ln early stage ALS, the individual can have any of the following symptoms,
Muscles Physical effects
0f the body, Mild symptoms may affect
more than one region.
Muscles characterized by: May experience symptoms such as:
Weak and so ft or stiff, tight and spastic Fatigue
. l
Cramping and twitching Poor balance
Atrophy (loss of muscle mass) Slurred words
Weak grip
|0087| In middle stage ALS, the individual can have any of the following symptoms.
Muscles Physical effects
Symptoms become more widespread. Some Unused muscles may cause contractures 7
muscles are paralyzed, while others are joints become rigid, l and may be
weakened or unaffected. Twitching may deformed. As a result of weak muscles, an
continue. individual with ALS may:
< Require help to stand
l Have difficulty eating and wing,
causing g
Have difficulty breathing, especially lying
1 down
Some people with ALS experience bouts of
uncontrolled and inappropriate laughing or
crying (called pseudobulbar affect or PBA).
In late stage ALS, the individual can have any of the following symptoms.
Muscles. Physical s
Most voluntary s are paralyzed. The Most people in the late stages of ALS have
ability to move air in and out of the lungs is severely limited ty and are unable to
severely compromised. care for their own needs.
Fatigue
Fuzzy thinking
Headaches
l Susceptibility to pneumonia
Speech may no longer be possible
Eating and drinking by mouth may no longer
be possible
As used herein, “amyotrophie lateral sclerosis” or “‘ALS" includes the
um ofneurodegcnerativc syndromes known under the names ot‘Classical (Chareot’ 3)
ALS, Lou Gehrig’s disease, motor neuron disease (MND). progressive bulbar palsy (PBP),
progressive muscular atrophy (PMA), primary lateral sclerosis (PLS), bulbar onset ALS.
WO 38814
spinal onset ALS and ALS with multi-system involvement ekera LC and Leigh PN.
Amyotrophic lateral sclerosis. Orphanet l of Rare Disease 2009, 4:3). Types ot‘ALS
include sporadic ALS. familial ALS, Western Pacific ALS, Juvenile ALS, and Hirayama
Disease.
Types of ALS include sporadic ALS, familial ALS, and variants. including
Western Pacific ALS. Juvenile ALS. and H'irayama Disease. The present disclosure es
a method for treating ALS. including sporadic ALS. familial ALS, and variants. including
Western Pacific ALS. Juvenile ALS, and Hirayama Disease.
Approximately 10% ol’cases ol‘.ALS are familial. The remaining 90% are
sporadic and though to be multifactorial, with both environmental and genetic components
buting to disease susceptibility. The genetics of both FALS and SALS is complex.
About 20% ol‘cases with autosomal dominant FALS and 2% of patients with SALS show
mutations in the copper/zinc superoxide dismutase (SODI) gene on chromosome 21.
Mutations in the gene are thought to cause disease through a toxic gain of function rather than
causing impairment ofthe antioxidant function of the SOD l enzyme. gh genes
different from other than SODl have been associated with familial ALS, including alsin
, senataxin (ALS4) or Angiogenin, the genetic defect remains to be identified in the
majority of cases.
Sporadic and familial ALS (SALS and FALS, respectively) are clinically and
pathologically similar. suggesting a common pathogenesis. Both forms produce similar
pathological hallmarks, including progressive muscle weakness, atrophy, and spasticity, each
of which reflects the degeneration and death of upper and lower motor s. Denervation
of the respiratory muscles and diaphragm is lly the fatal event. In current l
practice. the terms “bulbar onset ALS” and “spinal onset ALS" have replaced the terms PBP
and Charchot‘s ALS. Approximately two thirds of patients with typical ALS have a spinal
Form of the disease (limb onset) and present symptoms related to focal muscle weakness and
wasting. where the symptoms may start either distally or proximal ly in the upper and lower
limbs. Gradually. spasticity may develop in the weakened atrophic limbs, affecting manual
dexterity and gait. Patients with bulbar onset Al's-S y present with hria and
dysphagia for solid or liquids, and limbs symptoms can, develop almost aneously with
bulbar symptoms. and in the vast majority of cases will occur within 1—2 years. Paralysis is
progressive and leads to death due to respiratory failure within ‘2-3 years for bulhar onset
cases and 3-5 years for limb onset ALS cases.
|0093| Western Pacific ALS is a unique neurological disease initially identified
among the Chamorro people of Guam and is terized by a combination of symptoms
including stooped posture, a blank expressionless face, dementia. slow shuffling movement, a
resting tremor that stops upon rate action, slow movements, and muscle atrophy that
results in muscles dipping down in the hand. Some patients have Parkinsonism features
combined with dementia (Parkinsonism Dementia Complex, PDC). in still others, only
dementia is observed. Neuropathologically, all clinical forms of the disease result in a
specific feature, neurofibrillary tangles, found in the cortex and in the spinal cord. Because
the disease has aspects that resemble amyotrophic lateral sclerosis (ALS), Parkinson’s disease
(PD) and Alzheimer's e (AD), this disease is known as n Pacific ALS or
amyotrophic l scierosis—Parkinsonism dementia complex of Guam. (ALS—PDC) and is
also known as lytico-bodig.
Juvenile ALS is an adolescent motor neuron disease that is clinically
indistinguishable from ALS. Onset is between ages of twelve and sixteen years and occurs
below the age of 25 years.
In Hirayama e, there is localized atrophy of one arm associated with
increased reflexes implicating the presence of upper and lower motor neuron damage.
However, Hirayama Disease involves a problem at the junction between the cervical spine
and the. skull where there is pressure on the cervical spinal cord. In order to detect I-Iirayama
Disease, an MRI of the neck needs to be performed in different ons including neck
flexion and extension.
[0096! Other syndromes related to the ALS spectrum of disorders include ssive
bulbar palsy (PBP), progressive ar atrophy (PMA), primary lateral sclerosis (PLS) and
ALS with multi-system involvement. The t disclosure es a method for treating a
syndrome related to the ALS spectrum of ers, such as progressive bulbar palsy (PEP),
progressive muscular atrophy (PMA). primary lateral sclerosis (PLS), or ALS with multi—
system involvement.
Progressive bulbar palsy (PBP) is a motor neuron disease. in which the nerves
supplying the hulbar muscles are attacked. PBP is characterized by the ration of
motor neurons in the cerebral cortex, spinal cord, brain stem. and pyramidal tracts.
Progressive bulbar palsy symptoms can include progressive difficulty with g, talking.
and swallowing. Patients can also exhibit reduced gag reflexes. weak l movements,
2014/000274
fasciculations. and weak movement of the facial muscles and . In advanced cases of
PBP, the patient may be unable to protrude their tongue or manipulate food in their mouth.
Progressive muscular atrophy (PMA, also Duchenne-Aran muscular atrophy
or Duchenne-Aran disease) is motor neuron disease which affects the lower motor neurons.
Symptoms ofPMA include atrophy. fasciculation, and muscle weakness. Some patients have
ms restricted to the arms or legs.
Primary lateral sclerosis (PLS) is a neurotnuscular disease characterized by
progressive muscle weakness in the voluntary muscles. PLS affects upper motor neurons.
Symptoms include difficulty with balance and weakness and stillness in the legs. Other
common symptoms are spasticity (involuntary muscle contraction due to the stretching of
). There may also be difficulty in breathing in the later stages ot‘the disease, causing
those patients who develop ventilatory failure. Hyperrellexia is another feature of PLS as
seen in patients presenting with the Babinski's sign. Some people present with nal
lability and bladder urgency, and occasionally people with PLS experience mild cognitive
changes detectable on neuropsychological testing, particularly on measures of ive
function.
in some ments, the benefits of administering the compositions to
alleviate the symptoms or treat ALS can be evaluated by the following tests: a reduction in
the rate of decrease in the ALSFRS-R score, the Manual Muscle Testing (MMT) score, the
Slow Vital Capacity (VC) percent predicted value, the ALE-Specific Quality of Life
(ALSSQoL) score, and EuroQol~5 Dimensions (EQ—SD) Health Outcomes Scale score.
Another suitable test for evaluation includes a reduction in the rate of increase in the Zarit
Burden Interview (ZBI) score. r suitable test for evaluation is the use of electrical
nce phy as a ker (Rutkove et at, oph l Scler. 2012 Sep;
l3(5):439—4). In some ments, the rate of decrease in, or the symptom measured by,
the ALSFRS-R score is d by at least 15% as compared to an individual with AIS who
is not administered S-oxprenolol.
Beta Blockers
] The methods described herein comprise administration of compositions
comprising beta blockers. Beta blockers, which are used to treat hypertension, can be used
for preventing the onset of amyotrophic lateral sclerosis and for treating amyotrophic lateral
sclerosis. For example, the use ot‘a beta blocker in an individual with ALS has shown that
the dual has prolonged al compared to an individual with ALS that did not
receive a beta blocker. Other benefits ofthe use ofa beta blocker include preservation of
lean body mass and prevention of body weight loss. These eflects suggest that beta blockers
can be used to treat AIS, delay the development of ALS, alleviate the symptoms of ALSfi and
improve the quality of life for ALS patients.
|0102] ln some embodiments the beta blocker has intrinsic homimetic ty
(ISA). In some embodiments, the beta blocker does not have intrinsic sympathomimetic
activity (lSA). Intrinsic sympathotnimetic activity is used to refer to beta blockers that can
Show both agonism and antagonism at a, given beta receptor, ing on the concentration
of the agent (beta blocker) and the concentration of the antagonized agent.
In some embodiments, where the beta blocker ns one chiral centeri the
beta blocker is the enantiomerically enriched S-enantiomer or a pharmaceutically acceptable
salt thereof.
In some embodiments, the beta blocker is selected from the group consisting
ofacebutolol, atenolol, betaxolol, bisoprolol, carteolol, celeprolo]= labetaloL metoprolol,
l. nebivolol. oxprenolol, penbutolol, pindolol, propanolol, sotalol, esmolol, earvediloh
timolol, bopindolol, medroxalol, bucindololi levobunolol. metipranolol, celiprolol and
propat‘enone. ln some embodiments, the beta blocker is oxprenolol. ()xprenolol is a non-
selective beta blocker which possesses some sic sympathomiinetic activity.
|0105] in some embodiments, the beta blocker also has partial 5-HT; A rn
activity. The 5-HT, A receptor is a subtype of 5~HT receptor that binds the endogenous
netu'otransmitter serotonin (5-hydroxytryptamine, 5-HT). Oxprenolol is a partial S-I-I‘I'la
agonist.
tiomerically enriched compositions of beta blockers
06] The methods described herein comprise administration ol’an S-
enantiomerically ed composition of a beta r or a phamiaceutically acceptable salt
f (for example comprising an enantiomeric excess of at least about 99% of a beta
blocker). The present sure also provides such compositions which are useful for the
methods disclosed herein.
When a compound has a chiral center, the compound can exist in optically
active forms. Optically active compounds have the ability to rotate the plane of plane-
polarized light. in describing an optically active compound, the prefixes R and S are used to
denote the absolute configuration of the molecule about its chiral center(s). The prefixes “d”
and “l” or (+) and (—) are employed to designate the sign of rotation of plane-polarized light
by the compound, with (-) or 1 meaning that the compound is “levorotalory” and with (+) or 0.
meaning that the compound is “dextrorotatory.” There is no correlation between
nomenclature for the absolute stereochemistry and for the rotation of an enantiomer. For a
given al structure, these compounds, called “stereoisomers,” are identical except that
they are mirror images of one another. A c stereoisomer can also be referred to as an
“enantiomer,” and a mixture of such isomers is often called an “enantiomerie” or “racemic”
mixture. When a compound has one chiral center, there are two enantiiomers: the S-
enantiomer and the R—enantiomer.
[0.108] The compositions described herein are enantiomerically enriched for S—
enantiomer. For example, in some embodiments, the composition comprises an enantiomeric
excess of at least about 1%, %, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%,
60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% ofS—enantiomer ofthe beta r. In some
embodiments, the composition comprises an enantiomeric excess of at least about 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9% of S-enantiomer of the beta r.
In some embodiments, the composition comprises an enantiomeric excess of at least about
90%. 95%, 98%, 99%, or 100%, up to the detectable limit of purity, of S—enantiomer ot‘the
beta r. In some embodiments, the composition comprises an enantiomeric excess of
any t 1-4%, 5-9%, 10-11%, 20-29%, 30-39%, 40-49%, 50-59%, 60-69%, 70-79%, 80-
89%, 90—99, or 100% of tiomer of the beta blocker. In some ments, the
composition comprises an enantiomeric excess of at least about 99% or 100% of S-
enantiomer of the beta blocker (i.e., pure S—enantiomer of the beta blocker). In some
embodiments, the composition comprises an enantiomeric excess ot‘al least 99.1, 99.2, 99.3,
99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 1.00% 01' S—enantiomer ot‘the beta blocker (i.e., pure S—
enantiomer of the beta blocker). Methods of making enantiomerically enriched compositions
of beta blockers are known in the art.
In some ments, the beta blocker is ed from the group consisting
ofacebutolol, atenolol, lol, bisoprolol, lol, celeprolol, labctalol, metoprolol,
nadolol, lol, oxprenolol, penbutolol, pindolol, propanolol, sotalol, esmolol. carvedilol,
titnolol, bopindolol, medroxalol, bucindolol, levobunolol, metipranolol, celiprolol and
propafcnone or a pharmaceuticahy acceptable salt thereof.
WO 38814
|0110| In some embodiments, the beta blocker is oxprenolol or a pharmaceutically
acceptable salt thereof. Oxprenolol is l~[2—(allyloxy)phenoxy]~3—(isopropylamino)propan—2-
01. The structure ol‘oxprenolol is shown below.
@OWNYCMH/ OWV’CHZ CH3
Oxprenolol is a compound with one chiral . As a racemic mixture. there
is a mixture of )-oxprenolol and (S)-(~)—oxprenolol. Analytical s. such as
HPLC, can be used for separation and quantification oi'(R)-(+)-oxprenolol and (S345)-
oxprenolol in mixtures. The structures of )~oxprenolol and (S)—(i}0xprenolol are
shown below.
CE WCHZf3O (R)- +( ) oxprenolol or R oxprenolol. -
/H“Y\H (R)~1—(2—( allyloxy)phenoxy)-3~
O ‘
- N CH 3
(isopropylammo)propan—2—ol. 1
0H 1 1 lot S-ox renolol
O.\/"l\/NH, H (8') (- ~ -) oxpreno o p
(19-1—(2—(al1yloxy)phenoxy)
(isopropylamino)propan~2~o1
The compositions described herein are enantiomerically enriched for S-
oxpreno1ol. For example. in some ments, the composition comprises an enantiomeric
excess ofat least about 1%, 5%, 10%. 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%. 55%,
60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% ot‘S—oxprenolol. 1n some ments, the
composition comprises an enantiomeric excess of at least about 90%, 91%. 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99%, or 99.9% of S—oxprenolol. in some embodiments, the
composition comprises an enantiomeric excess of at least about 90%, 95%, 98%, 99%, or
100%, up to the detectable limit of purity, of enolol. 111 some embodiments, the
composition comprises an enantiomeric excess of any of about 1-4%, 5—9%. 10-11%. 20-
29%. . 40-49%. 50—59%. 60—6. %. 70—79%, 80—89%, 90—99. or 100% of S—oxprenolol.
In some embodiments, the composition comprises an enantiomefic excess of at least about
99% or 100% of S—oxprenolol (i.e.. pure S—oxprenolol). In some embodiments, the
composition comprises an enantiomeric excess of at least 99.1, 99.2, 99.3, 99.4, 99.5, 99.6,
9.9.7, 9.9.8, 9.9.9 or 100% of Svoxprenolol (i.e., pure Svoxprenolol). Methods of making
enantiomerically enriched compositions ofoxprenolol are known. in the art.
2014/000274
|0113| Two main routes are established for obtaining enantiomerically enriched
compounds: (1) asymmetric syntheses and ('2) racemic resolutions. (R. A. n: The
Industrial Syn/hens ofOptically Active Compounds, in Miklés Simonyi (editor). Problems
and s ifChiraZ Molecules, Akadémiai Kiado, Budapest, 1990, S. 349—386). The
syntheses give medium-high yields and excellent enantiomeric excess. but the resolutions are
d by 50% yield. Both technologies involve techniques such as dynamic kinetic
resolution (DKRV) and membrane-based extraction (Augustian J et al., s Biochemistry
Volume 45, issue 10. October 20l0, Pages 1587—1604). One method describes enantiomer
enrichment ot‘oxprenolol up to 68 % enantiomeric excess was achieved by using a cellulose
tris(3,5~dimethylpbenylcarbamate) (CTPC)-coated rayon—belt. (Yashima E. et 2d,.
edron: Asymmetry Volume 6, issue 8, August 1995, Pages l889ml 890).
The compositions described herein in some embodiments are present in
pharmaceutical compositions. The phannaceutical itions may further comprise one or
more pharmaceutically acceptable carrier (or cxcipicnts). A pharmaceutically-acceptable
excipient is a nce that is non-toxic and otherwise biologically suitable for
administration to a subject. Such excipients facilitate administration of the compounds
bed herein and are compatible with the active ingredient. Examples of
pharmaceutically—acceptable excipients include stabilizers, lubricants, surfactants. diluents.
anti-oxidants, binders, coloring agents, bulking agents, cmulsifierst or taste-modifying agents.
in some embodiments, the pharmaceutical composition is sterile.
Also provided here are unit dosage forms comprising a pharmaceutical
compositions described herein. These unit dosage forms can be stored in a suitable ing
in single or multiple unit dosages and may also be further sterilized and sealed. Unit dosage
Forms can be provided, for example, in the form of tablets, capsules, vials, and any other
forms described herein.
[01161 In some embodiments. there is provided a compositioa (such as a
pharmaceutical ition, for example a unit dosage) comprising oxprenolol or a
phamtaceutically acceptable salt thereof. wherein the composition is enantiomerically
enriched for S-oxprenolol (for example comprising an enantiomeric excess of at least about
99% ofS—oxprenolol), wherein the amount ol‘S—oxprenolol in the ition (such as
pharmaceutical composition) is included in any of the following ranges: about 5 to about 10
mg. about 10 to about 20 mg, about 20 to about 30 mg, about 30 to about 40 mg, about 40 to
about 50 mg, about 50 to about 60 mg, about 60 to about 70 mg, about 70 to about 80 mg.
2014/000274
about 80 to about 90 mg, about 90 to about 100 mg, about 100 to about 110 mg, about 110 to
about 120 mg, about 120 to about 130 mg, about 130 to about 140 mg, about 140 to about
150 mg, about 150 to about 160 mg. in some embodiments, the amount of S-oxprenolol in
the composition is about 20 to about 160 mg, including for example about 50 to about l 50
mg. 80 to about 150 mg. about 90 to about 140 mg, about 100 to about 120 mg. In some
embodiments, the composition is suitable for oral administration.
In some embodiments, the composition is provided in a slow release form.
For e, olol can be administered in slow release form. (Eur J Drug Metab
Pharmacokinet. 1998 Apr—Jun:23(2):l78-84; t PN, Bennett J, Bradbrook 1, Francis J,
John VA, Rogers H, Turner P, Wanington SJ. Br J Clin Pharmacol. 1985;19 Suppl 221718—
1758; and Woods KL, Jack DB, Kendall MJ, Halsey A, O’Donnell ML, gton. SJ, John
VA. Br J Clin Pharmacol. 1985; I9 Suppl 741778-1848.)
Also provided are articles of manufacture comprising the compositions,
formulations, and unit dosages described herein in le packaging for use in the methods
of treatment, methods of administration, and dosage regimens described herein. Suitable
packaging for compositions described herein are known in the an, and include, for example,
Vial (such as sealed , vessels (such as sealed vessels), ampules, bottles, jars, flexible
packaging (cg, sealed Mylar or plastic bags), and the like. These articles ofmanufacture
may further be ized and/or sealed.
Dosages and Administration Route
The dosage of the itions described herein stered to an individual
(such as a human) may vary with the particular composition, the method of administration,
and the particular stage of amyotrophic lateral sclerosis. The amount should be suflicient to
produce a desirable response, such as a therapeutic or prophylactic response against
amyotrophic lateral sclerosis. in some embodiments, the amount of the composition is a
therapeutically effective amount. In some ments. that amount of the composition is a
prophylactically effective amount. In some embodiments, the amount of total oxprenolol in
the composition is below the level that induces a toxicological effect (1?. c an effect above a
clinically able level of toxicity) or is at a level where a potential side effect can be
controlled or tolerated when the composition is administered to the individual.
In some embodiments, the amount of an S—enantiomerically enriched
composition ofa beta blocker or a pharmaceutical ly acceptable salt thereof (e.g., —
oxprenolol) in the ition is included in any of the ing ranges: about 0.5 to about
mg, about 5 to about 10 mg, about 10 to about 15 mg, about 15 to about 20 mg, about 20 to
about 25 mg, about 20 to about 50 mg, about 25 to about 50 mg, about 50 to about 75 mg,
about 50 to about 100 mg, about 75 to about 100 mg, about 100 to about 1.25 mg, about 125
to about 150 mg. about 150 to about 175 mg, about 175 to about 200 mg, In some
embodiments, the amount ol" an S-enantiomerically enriched composition of a beta blocker or
a pharmaceutically acceptable salt thereof (eg, S—oxprenolol) in the composition is included
in any of the following ranges: about 5 to about 10 mg, about 10 to about 20 mg, about 20 to
about 30 mg, about 30 to about 40 mg, about 40 to about: 50 mg, about 50 to about 60 mg,
about 60 to about 70 mg. about 70 to about 80 mg, about 80 to about 90 mg, about 90 to
about 100 mg, about IOO to about [10 mg. about i 10 to about 1'20 mg, about 120 to about
[30 mg, about 130 to about 140 mg, about 140 to about 150 mg, about l50 to about [60 mg.
in smne embodiments, the amount of an S-enantiomerically enriched ition ofa beta
blocker or a pharmaceutically acceptable salt thereof (cg. S—oxprenolol) in the composition
is about 20 to about 160 mg, including for example about 50 to about 150 mg, 80 to about
150 mg, about 90 to about 140 mg, about 100 to about 120 mg.
in some embodiments, the amount of an S—enantiomerically enriched
composition ot‘a beta blocker or a phannaceutically acceptable salt thereof (eg, S—
oxprenolol) in the composition includes at least about any ol‘0.1 , 0.5 mg/kg, 1 rug/kg.
mg/kg. 5 mg/kg, 7.5 mg/kg, 10 tug/kg, l5 mg/kg, or 20 mg/kg. 111 some embodiments, the
amount of an S-enantiomerically enriched composition of a beta blocker or a
pharmaceutically acceptable salt thereof (_e.g., S-oxprenolol) in the composition es less
than about any of35 mg/kg, 30 mg/kg, 25 mg/kg, 20 mg/kg, 15 rug/kg, 10 mg/kg, 5 mg/kg,
2.5 mg/kg, 2 mg/kg, 1 mg/kg, 0.5 mgkg, or 0.1 mg/kg.
Exemplary dosing frequencies include, but are not limited to, weekly without
break; , three out of four weeks; once every three weeks; once every two weeks;
weekly, two out e weeks. 111 some embodiments, the composition is administered about
once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 6 weeks, or once
every 8 weeks. In some embodiments, the composition is administered at least about any of
1x, 2X, 3x, 4x, 5x, 6x, or 7X (Ila, daily) a week. In some embodiments, the intervals between
each administration are less than about any of 6 months, 3 months. 1 month, 20 days, 15,
days, 12 days, 10 days, 9 days. 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, or 1
day. in some embodiments, the intervals n each administration are more than about
any of 1 month. 2 months, 3 months, 4 months, 5 months, 6 months, 8 months, or 12 months.
In some embodiments, there is no break in the dosing schedule. In some embodiments, the
interval between each stration is no more than about a week. In some embodiments,
the composition is administered daily. in some embodiments, the composition is
administered twice daily. in some embodiments, the composition is stered at least
once (such as at least any ol‘2x, 3x, or 4x) daily.
The administration of the composition can be extended over an extended
period oftime. such as from about a month up to about seven years or life-long. In some
embodiments, the composition is administered over a period of at least about any of 2, 3, 4, 5,
6, 7, 8, 9, 10, l 1, l2, 18, 24, 30, 36. 48, 60, 72, or 84 months or life-long. In some
embodiments, the composition is administered over a period of at least one month, wherein
the interval between each administration is no more than about a week.
The itions described herein can be administered to an dual (such
as human) via various routes, including, for example, intravenous, ultra—arterial,
intraperitoneal, intraportal, ulmonaiy. oral, inhalation, intravesicular, intramuscular,
intra-tracheal, subcutaneous, intraocular, intrathecal, transmucosai, and transdermal. In some
embodiments. sustained continuous release formulation of the composition may be used.
Once improvement of the patients disease has occurred, the dose may be
adjusted for preventative or nance treatment. For example. the dosage or the
frequency of stration, or both, may be reduced as a function of the ms, to a
level at which the desired therapeutic or prophylactic effect is maintained. Ol‘course, if
symptoms have been alleviated to an appropriate level, treatment may cease. Patients may,
however, require intermittent treatment on a long-term basis upon any recurrence of
symptoms. Patients may also require chronic treatment on a long-term basis.
Pharmaceutical Formulations and stration
The ceutical, compositions described herein may be formulated as
solutions, emulsions, suspensions, dispersions, or inclusion complexes such as cyclodextrins
in suitable pharmaceutical solvents or carriers, or as pills. tablets, lozenges. itories,
sachets, dragees, granules, s, powders for reconstitution. or capsules along with solid
carriers according to conventional methods known in the art for preparation of various dosage
forms. Pharmaceutical compositions ofthe embodiments may be administered by a le
route of delivery, such as oral, eral, rectal. nasal, topical, or ocular routes, or by
inhalation. Preferably, the compositions are formulated for intravenous or oral
administration.
For oral administration, the compositions may be ed in a solid form.
such as a tablet or capsule, or as a solution, emulsion, or suspension. Oral tablets may
include the active ingredient(s) mixed with ible pharmaceutically acceptable
excipients such as ts, disintegrating agents, binding agents, lubricating agents,
sweetening , ng agents, coloring agents and preservative agents. Suitable inert
fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch.
sugar, glucose, methyl cellulose, magnesium te, niannitol. sorbitol, and the like.
Exemplary liquid oral ents include l, glycerol, water, and the like. Starch,
polyvinyl-pyrrolidone (PVP), sodium. starch glycolatc, microcrystalline cellulose, and alginic
acid are ary disintegrating agent's. Binding agents may include starch and gelatin.
The lubricating agent, it‘present, may be magnesium stearate, stearic acid, or talc. if desired,
the tablets may be coated with a material such as glyceryl rnonostearate or glyceryl distearate
to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating. The
oral formulations may be presented as discrete units such as capsules, cachets or tablets. each
containing a ermined amount of the active ingredient; as a powder or granules; as a
solution or a suspension in an aqueous liquid or a non—aqueous ; or as an oilvin—water
liquid emulsion or a in-oil liquid emulsion. The active ingredient may also be presented
as a bolus, electuary or paste.
Capsules for oral administration include hard and soft gelatin capsules. To
prepare hard n capsules, active ingredient(s) may be mixed with a solid, semi-solid, or
liquid diluent. Soft gelatin capsules may be prepared by mixing the active ingredient with
water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di—
glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
[0129! A tablet may be made by compression or moulding, optionally with one or
more accessory ients. Compressed tablets may he prepared by compressingr in a
suitable machine the active ingredient in a free—flowing form such as a powder or granules,
optionally mixed with a binder (cg nc, gelatin, hydroxypropylmethyl cellulose),
lubricant, inert diluent, preservative, disintegrant (cg sodium starch glycolate, cross-linked
ne, cross—linked sodium carboxymethyl cellulose), surface—active or dispersing agent.
Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered
compound moistened with an inert liquid diluent. The tablets may optionally be coated or
scored and may be formulated so as to provide slow or controlled release of the active
ingredient therein using, for example, hydroxypropylmethylcellulose in varying proportions
to provide desired release profile.
Liquids for oral administration may be in the form of sions, ons,
emulsions, or syrups, or may be lyophilized or presented as a dry product for reconstitution
with water or other suitable vehicle before use. Such liquid itions may optionally
contain: phannaceutiwily-acceptable excipients such as suspending agents (for example,
sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose,
carboxynretliylcellulose, aluminum stearate gel and the like); non—aqueous vehicles, e.g., oil
(for example, almond oil or fractionated coconut oil), propylene , ethyl alcohol, or
water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid);
wetting agents such as lecithin; and, if desired. flavoring or ng agents.
] For parenteral use, including intravenous, intramuscular, intraperitoneal,
intranasal, or aneous routes, the itions may be ed in e aqueous
solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally
acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium
de, Such forms may be presented in unit-dose form such as ampoules or disposable
injection devices, in niulti-dose forms such as Vials from which the appropriate dose may be
withdrawn, or in a solid form or pres-concentrate that can be used to prepare an injeetable
formulation Formulations le for parenteral including intravenous administration
include aqueous and non~aqueous sterile injection solutions which may contain anti—oxidants,
buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the
intended recipient; and aqueous and non-aqueous sterile suspensions which may include
suspending agents and thickening agents. The formulations may be presented in unit-dose or
multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze—
dried ilised) condition requiring only the addition ofthe sterile liquid carrier, for
example water for injections, immediately prior to use. Extemporaneous injection solutions
and suspensions may be prepared from sterile powders, granules and tablets of the kind
previously described.
red unit dosage 'l'ormulations are those containing a daily dose or unit,
daily sub—dose or an riate on thereof, of an active ingredient.
Drug ations
The methods of the embodiments comprise administering an effective amount
of at least one compound of the embodiments; optionally the compound may be administered
in combination with one or more onal therapeutic agents, particularly therapeutic agents
known to be useful for treating a amyotrophic lateral sclerosis afflicting the subject.
The additional active ingredients may be administered in a. separate
ceutical ition from a compound of the embodiments or may be included with a
nd of the ments in a single pharmaceutical composition. The additional active
ingredients may be administered simultaneously with, prior to, or after administration of a
compound of the embodiments.
In certain embodiments, the additional therapeutic agent is selected from the
group consisting ofCK-2017357, olesoxime (TRO 19622), arimoclomol, riluzole, tretionin
and tazone HC 1, AVP-923, memantine, talampanel. tauroursodeoxycholic acid
(TUDCA), thalidomide, olanzapine, KNS—760704, lithium carbonate, NPOOI, ONO-2506PO,
tamoxifen, creatine monohydrate, coenzymc Q l 0, YAMSO, sodium phenylbutyratc,
pyrimethamine, R(+)pramipexole dihydrochloride monohydrate, vitamin E, minocycline,
topiramate, gabapentin, Ol 50, stem cell injections, , autologous bone
marrow—derived stem cells. ceftriaxone, E0302 (mecobalamin), MCL 186, glatiramer acetate,
insulin-like growth factor- 1 (lGIi -1), 1518 333611, sNN 002‘), GSK1223249, brain—derived
neurotrophic factor (BDNFL and anti-CD4OL antibody,
Kits
The present, application also provides kits, medicines, compositions, and unit
dosage forms for use in any of the methods described herein‘
Kits provided herein include one or more containers comprising any one of the
compositions described herein and/or other agent(s), and in sortie embodiments, further
comprise ctions for use in accordance with any of the methods described herein The
kit may further comprise a description of selection of individual suitable for treatment,
Instructions supplied in the kits of the invention are typically n instructions on a label or
package insert (e.g., a paper sheet ed in the kit). but machine—readable instructions
‘ ' . I .
(e g v v I I v 3 x v ( » v
. 1‘ L
‘9 ctions carried on a magnetic or optical stor igc disk) are also accept tbleg .
|0138| For example. in some embodiments, the kit ses a) an S-
enantiomerically enriched composition of a beta blocker or a pharmaceutically acceptable salt
thereol‘(e.g.. S-oxprenolol) and a pharmaceutically able carrier and b) instructions for
administering the composition for treatment ot'amyotrophic lateral sclerosis.
The kits of the invention are in suitable ing. Suitable packaging
include, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or
plastic bags), and the like. Kits may ally provide additional components such as
buffers and retative information. The present application thus also es articles of
manufacture, which include vials (such as sealed vials), bottles, jars. flexible packaging, and
the like.
The instructions relating to the use of the compositions generally e
information as to dosage, dosing schedule, and route of administration for the intended
treatment. The containers may be unit doses, bulk packages (e. g.. multi—dose packages) or
sub-unit doses. For example, kits may be provided that contain sufficient dosages of S—
olol as disclosed herein to provide effective treatment ofan individual for an extended
period, such as any ot‘a week, 8 days, 9 days, 10 days, 1 l days, 12 days, 13 days, 2 weeks, 3
weeks. 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9
months, or more. Kits may also include multiple unit doses of the pharmaceutical
itions and instructions for use and packaged in quantities ent for storage and
use in pharmacies, for example, hospital pharmacies and compounding pharmacies.
Also provided are medicines, compositions, and unit dosage forms useful for
the methods bed herein. For example, the present disclosure provides, in some
embodiments, an tiomerically enriched composition of a beta blocker or a
phatmaceutically able salt thereof (em, S—oxprenolol) for treating amyotrophic lateral
sis in an individual having amyotrophic lateral sclerosis. The present disclosure
provides, in some embodiments, an S—enantiornerically enriched composition of a beta
blocker or a phannaceutically acceptable salt thereof (e.g., S-oxprenolol) for prolonging
survival of an individual having atnyotrophic lateral sclerosis. The t disclosure
provides, in some embodiments, an S-enantiomerically enriched composition of a beta
blocker or a pharmaceutically acceptable salt thereof (e.g., enolol) for delaying the
development of amyotrophic lateral sclerosis in an individual having amyotrophic lateral
sclerosis. The present disclosure provides, in some embodiments, an tiomerically
enriched composition ot‘a beta blocker or a pharrnaeeutically acceptable salt thereof (e.g., S-
oxprenolol) for ting lean mass loss of an individual having amyotrophie lateral
sclerosis. The t disclosure provides“ in some embodiments, an S-enantioinerically
enriched ition ol‘a beta blocker or a phannaceutically acceptable salt f (egt, S-
oxprenolol) for preventing muscle g of an individual having amyotrophic lateral
sclerosis. The present disclosure provides in some embodiments, an S-enantiomerically
enriched composition of a beta blocker or a pharmaceutically acceptable salt f (e.g., S—
oxprenolol) for improving quality of life in an individual having amyotrophic lateral
sclerosis.
For example. the t disclosure es, in some embodiments, an S-
enantiomerically enriched composition of a beta blocker or a pharmaceutically acceptable salt
thereof (e.g., S-oxprenolol) for the manufacture of a medicament for treating amyotrophie
lateral sclerosis in an individual having amyotrophic lateral sclerosis. The present disclosure
provides, in some embodiments, an S-enantiomerically enriched composition ofa beta
blocker or a pharmaceutically acceptable salt thereof (cg. S—oxprenolol) for the manufacture
of a medicament for prolonging survival of an individual having ophic lateral
sclerosis. The present disclosure provides, in some ments, an S—enantiomerically
enriched composition of a beta blocker or a pharmaceutically acceptable salt thereof (emg S-
oxprenolol) for the manufacture of a medicament for ng the development of
amyotrophic lateral sclerosis in an individual having amyotrophic lateral sclerosis. The
present disclosure provides, in some embodiments, an S—enantiomerically enriched
ition of a beta blocker or a ceutically able salt thereof (e.g S-
oxprenolol) for the manufacture of a medicament for preventing lean mass loss of an
individual having amyotrophic lateral sclerosis. The present disclosure provides. in some
embodiments, an S-enantiomerically enriched composition of a beta blocker or a
pharmaceutically acceptable salt f (e.g., S—oxprenolol) for the manufacture ofa
medicament for preventing muscle wasting ofan individual having amyotrophic lateral
sclerosis. The present disclosure provides, in some ments, an timnerically
enriched composition of a beta blocker or a pharmaceutically acceptable salt thereof (egq —
oxprenolol) for the manufacture of a medicament for improving quality of life in an
individual having amyotrophic lateral sclerosis.
Those skilled in the art will recognize that several embodiments are possible
within the scope and spirit of this invention. The ion will now he described in greater
detail by reference to the following non-limiting examples. The following examples further
illustrate the invention but. of course, should not be construed as in any way limiting its
scope.
Examples
e 1. Synthesis renolol
The synthesis of S—oxprenolol is shown in Scheme 1.
9 ma
0 /fl_§‘(\/fl7 ”\vox/\
L> I n O L \
@OH _, @O‘VR 3
/ /\o/\/\fi’k
OH OH
OH iPrNH2
(S)—0xpre nolol
1 2
Scheme 1
Preparation of2—(aZ/.)zlo.ryi{)plzenol
To a solution of ol (1) (40.0 g, 0.364 mol) in acetone (160 mL) was
added potassium carbonate (50.0 g, 0.363 mol) portion-wise at room temperature, over a
period of 30 minutes. After the addition was complete the e was d at room
temperature for l hour. Ally] bromide (31 .0 ml... 0.358 mol) was then added over a period of
minutes. and the reaction heated to 60—70 0C for 6 hours. The reaction was allowed to
cool. then water and ethyl acetate were added and the mixture was separated. The organic
layer was dried (MgSO4) and the solvent evaporated to give 2~(allyloxy)phenol. (2) (46.2 g)
as a 7:3 mixture of mono and his alkylated al.
'H NMR (300 MHZ, CDCl3)(56.93'-6.77(1’U, 4H), 6.05 (m. 1H), 5.41 (dd. 1H),
.30 (in. Ill), 4.61 (d, 211). LCMS: Rt 0.70 min, [Mill]f 148.9. 70%.
Preparation QfS—oxprermlol
CsF (22.8 g. 0.150 mol) was added to a solution of2~(allyloxy)phenot (7.50 g,
0.050 mol) in DMF (100 mL) and stirred for 1 hour at room temperature. (S)-Glycidyl
nosylate (13.0 g, 0.050 mol) was added and the reaction stirred for ‘72 hours at room
temperature, then added dropwise to iPrNHg ('97 mL, 1.26 mol) and stirred overnight. The
reaction mixture was diluted with EtOAe (150 mL) and water (200 mL) and the solids
removed by filtration. The phases were separated and the organic layer washed with water
(100 ml.) then brine (100 ml). dried over MgSO4 and concentrated. Purification by column
chromatography (5—10% /DCM then 5% (17% NI—h/MeOI-l) in DCM) gave (S)—
oxprenolol (4.67 g. 20%) as a brown solid.
|0148| '11 NMR 1300 M112, c1103) 0‘ 6.92-6.89 (m, 211), 6.82-6.79 (m, 211), 5.99 (111.
111), 5.37 (d, 1H), 5.21 (d, 11114870» 3, 1H), 4.51 (d, 2H), 3.85 ((1,211), 3.80011. 1H),
2.69-2.61 (m, 2H), 2.47 (m. 1H), 1.48 (b;- s. 1H),, 0.93 (d, 6H).
[01.4.9] LCMS: R1 1.78 min, [M+H]" 266.1, 100%.
Example 2. Synthesis qu—Oxprenolol
The synthesis of S—oxprenolol is shown in Scheme 2.
[N02
1) o '59 / Ml“
(3)4 b _—::J/
/\ /O‘\/§~ a
Cfov\/ . ‘ J\
O H
OH 2119mm2
2 (m-oxprenolol
Scheme 2
ation Qf'R—oxprenolol
CsF (2.95 g, 19.4 11111101) and K3C03 (17.3 g, 125 11111101) were added to a
solution ot‘2-(allyloxy)phenol (14.4 g, 96.2 mmol) in DMF (250 mL) and stirred for 30
minutes at room temperature. (R)—Glycidyl11osylate (25.0 g, 96.4 11111101) was added and the
reaction d for 48 hours at room temperature. iPrNHg (190 mL, 2.2] mol) was added in
one portion and the reaction stirred for 72 hours. The reaction mixture was diluted with
water (1.0 L) and ted with EtOAc (3 x 300 mL). The combined organics were washed
with HCl (2.0 M, 3 x 300 mL). The aqueous layer was pH adjusted to pH 12 with NaOH (2.0
M) and extracted into EtOAc (2 x 500 . This was washed with 1 :1 water/brine (3 x 500
1111.), then with brine (500 ml), dried over NaZSO4 and concentrated. The crude solid was
triturated from heptanes, filtered and dried under vacuum at 40 °C overnight to give (R)—
oxprenolol (24.5 g, 69%) as a brown solid.
1H NMR (300 MHZ. CDC13)5 6.92-6.89 (m, 2H), 6.82-6.79 (m, 2H), 5.99 (111.,
1H), 5.57 (d, 1H), 5.21 (d, 1H), 4.87 (br s, 1H), 4.51 (d, 2H). 3.85 (d, 2H), 3.80 (m, 1H),
2.69—2.6l (in, 2H), 2.47 (m, 1H), 1.48 (br s. 1H). 0.93 (d, 6H).
LCMS: Rt 179 min, [MHLJI]f 266.1, 99%.
Example 3. Study ol with B6SJL~Tg(SODI *G93A)IGur/JALS .Mouse
diode!
Transgenic mice xpressing a high copy number (25 copies) of mutated
human SOD] gene with a G93A point mutation. i.e., B6SJL-TgN [SOD l -G93A] lGur ((3 1H-
2014/000274
693A transgenic mice. JR2726; Hemizygote) y M E, et al., Science, 264, 1772-1775.
1994) (“‘G93A SODl B6SJL hybrid (G93A) model”), were used. As shown in a diagram in
Figure 1, the transgenic mice display muscle weakness and atrophy by 90 to 100 days of age.
and typically die near 130 days ot‘age.
An intervention study was performed with S‘oxprenolol (l Omg/kg/day) in the
G93A SOD] BéSJL hybrid (G93A) model after onset ol’ALS. Onset ease was defined
as peak body weight as well as the beam walk and splay neurological scores as suggested by
Ludolph et al. 2007. (Ludolph AC, Bendotti C, Blaugrund E, Hengerer B, Loffler JP, Martin
J Moussaoui S. Robberech’t W Scott: S, Silani V5 Van Den Be rg LH
, Meininger V.) Meyer T. ,
(ENMC Group For The ishment Of Guidelines For The Conduct OfPreclinical And
Proof Ot‘Concept Studies in ALS/MND ). 2007. Guidelines for the preclinical in vivo
evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC
international workshop. Arrzyotmphic Lateral Sclerosis 8: 217—223.) There were 15 mice in
the placebo group. There were 16 mice in the S-oxprenolol group.
The primary endpoint was survival, humanely defined as the ability of the
animal to right itself in 30 s after being laid on its side. Secondary endpoints were
body weight, body ition, spontameous activity and food intake. Body weight of the
animals was assessed weekly until onset of disease. Additionally, body composition (fat
mass and lean body mass) was assessed using NMR scans (EchoMRl-lOO. Echo Medical
Systems, Houston, USA) every 4 days. After onset of disease, body weight and body
composition were assessed every two days until the end of the study. All personal handling
the s was strictly blinded to the randomized treatment tion.
Example 4. Effect qu—Oxprenolol on Survival
To study the effect of S—oxprenolol on survival. survival was monitored over
time. Figure 2 shows the percent survival of mice that were administered with S—oxprenolol
at dosages of 10 day. As shown in Figure 2, mice re‘eiving S-oxprenolol had longer
survival than those in the o group. Treatment of G93A mice with 10 mg/kg/day ot‘S-
oxprenolol after onset of ALS significantly improved survival by about 33% compared to
placebo treated mice (56 vs 42 days after onset, respectively. HR: 0.39, 95%Cl: 0.l7l—0.88.
p= 0.0241, Figure 2). Median survival was improved from 28 days (placebo) to 37 days (S~
oxprenolol, ratio: 1.32, 95%Cl: 0.83-1.81).
|0158] Figure 3 shows the percent survival of mice that were administered S—
oxprenolol at a dosage of 10 mg/kg/day. One control group received S-pindolol at its
red dosage of 3 mg/kg/day. As shown in Figure 3. S-oxprenolol was significantly
superior to either placebo or S—pindolol at its preferred dose. The median survival after onset
ofALS symptoms was 28 days for the placebo group; 3] days for the S—pindolol group; and
37 days for the S-oxprenolol group.
Figure 4 shows the t survival of mice that were administered S—
oxprenolol at a dosage of 10 mg/kg/day, R-oxprenolol at a dosage of H) mg/kg/day,
oxprenolol at a dosage ol‘20 mg/kg/day, le at a dosage of 30 mg/kg/day, or propanolol
at a dosage of l0 mg/kg/day. There was also a o group. As shown in Figure 4, -
oxprenolol was significantly superior to either placebo or the other nds.
Example 5. Effect ofS—Oxprenolol on Body Weight
To study the effect of S—oxprenolol on body weight, body weight was
monitored over time.
|0161] Figure 5 shows the change of body weight (in grams per day alive after onset
ofALS symptoms) per survival day after ALS onset in mice administered S-oxprenolol at a
dosage of 10 mg/kg/day or S—pindolol at red dosage of 3 mgr'ltg/day. As shown in
Figure 5, mice receiving S—oxprenolol had body weight loss that was close to those
administered S-pindolol. Mice receiving S-oxprenolol had less body weight loss than those
in the placebo group.
e 6. Effects ofS—Oxprenolol an ving Lean Body Mass
To study the effect of the test compounds on lean body mass, lean mass was
determined at the end of the study.
In this experiment. all mice were killed using the 30 seconds endpoint and
hence all mice were equally diseased at the end of the study. Figure 6 shows the change in
lean body mass (in grams) of mice that were administered S—oxprenolol at a dosage of 10
mg’kg/day. As shown in Figure 6, rats receiving S—oxprenolol had less change in lean body
mass than those receiving a placebo. Wasting of lean mass was reduced by about 40% by
active treatment compared to placebo (p=0.18, Figure 6). This effect shows that S-oxprenolol
is effective in preserving lean body mass.
|0164| Figure 7 shows the change in lean body mass (in grams per day alive after
onset ofALS symptoms) per survival day after ALS onset of mice that were administered S~
oxprenolol at a dosage of 10 mg/kg/day or S-pindolol at preferred dosage of 3 mg/kg/day. As
shown in Figure 6, rats receiving S-oxprenolol had less change in lean body mass than those
receiving olol.
Example 7. Efjécts Q/‘S-OxpreIwIOI on Skeletal Muscle Atrophy
To study the effect of the test compounds on al muscle atrophy. the
skeletal muscle mass were determined at the end of the study.
Figures 8—1 1 show the mass ofvarious types of skeletal muscle (in grams) of
mice populations that were administered S-oxprenolol at a dosage of 10 mg/kg/day or a
placebo. Figure 8 shows results for gastroenemius muscle weight plotted with days after
onset for the placebo group. A trend for a correlation of days after onset (=survival) and
gastrocnemius weight was seen in placebo-treated mice. (R:-0.5(i, p=().18) Figure 9 shows
results for gastroenemius muscle weight plotted with days after onset for the S—oxprenolol
group. Figure 9 shows that with stration of enolol. the gastrocnemius weight in
the G93A ALS model is steady. There is no correlation ot'days after onset ival) for
gastrocnemius weight. 03, p-"~~O.94)
Figure 10 shows results for tibialis or muscle weight plotted with days
after onset for the placebo group. A trend for a correlation olidays after onset (=survival) and
tibialis anterior muscle weight was seen in placebo—treated mice. (R:-0.67, p=().097) Figure
1 l shows s for tibialis anterior muscle weight plotted with days after onset for the S—
oxprenolol group. Figure 11 shows that with administration of S-oxprenolol, the tibialis
anterior muscle weight in the G93A ALS model is steady. There is no correlation of days
after onset (=survival) for is anterior muscle. (R1015, p=0.72)
The loss of mass ol’the fiber type muscle gastroenemius showed a trend
for a correlation of survival (:4 days after onset oldisease‘ Figure 8), while mice treated with
S-oxprenolol (Figure 9) showed no correlation, indicating a muscle protective role ot‘S-
oxprenolol. The loss of mass of the mixed-fiber type muscle tibialis showed a strong trend
for a correlation of survival (= days after onset of disease, Figure 10), while mice treated with
S—oxprenolol showed no correlation e l I)? again indicating a muscle protective role of
S-oxprenolol.
Example 8. Effects ofS—Oxprenolol on Preserving Fat Mass
To study the effect of the test compounds on fat mass, the fat mass were
determined at the end of the study.
Figure [2 shows the change in fat mass (in grams) of mice administered S-
oxprenolol. As shown in Figure 12, rats receiving S-oxprenolol had no reduction in fat mass
than those in the placebo group. S-oxprenoloi had no effect on the loss offat: mass ('p>0.5,
Figure 12).
[0.171] Figure 13 shows the change in fat mass (in grams per day alive after onset of
ALS symptoms) per al day after ALS onset ofmiee that were administered S—
oxprenolol at a dosage of 10 day or S-pindolol at preferred dosage of 3 mg/kg/day. As
shown in Figure 13, rats receiving S-oxprenolol had less change in fat mass than those
receiving olol.
The ence between Figures 12 and 13 is explained by the survival. The
overall loss of fat mass is equal on the day the animals are euthanized. But mice treated with
S—oxprcnolol lived longer and therefore the loss of fat mass per day alive after onset of ALS
symptoms is lower (=overall fat loss divided by number of days alive after ALS onset).
Example 9. s QfS—Oxprenolol on improving outcome QfALS ed to R~
Orprenolol and Rilutek
|0173] To study the effect of S-oxprenolol on survival compared to R—oxprenolol and
rilutek, survival was monitored over time. Rilutek (leuzole. structure shown below) is used
for ng ALS.
0 3(Ri1utek)
|0174] Figure 14 shows the percent survivai of mice that were administered with S-
oxprenolol at dosages of 10 mg/kg/day or 20 mg/kg/day. Other groups of mice were
administered riluteh at a dosage of 30 mg/kg/day; propanolol at a dosage of 10 mg/kg/day;
olol (racemic) at a dosage of20 mg/kg/day; R—oxprenolol at a dosage of 10 mg/kg/day
or 20 mg/kg/day: or a placebo. The number of mice in each population is indicated as “n" in
Figure 14. As shown in Figure 14, mice receiving S-oxprenolol at a dosage of 20 mg/kg/day
had longer survival than other groups.
2014/000274
|0175| The statistical data for Figure 14 is shown below. “HR” refers to hazard ratio.
“95% Cl" is confidence interval. “p" refers to p value.
Table 1: Statistical data for Figure 14 (for all mice)
Comparison (dosage in mg/kg/day) 95% C1 p value
Rilutek (30) vs. placebo . 0.55-l .46
Propanolol (10) vs. placebo l 0.73 045—! .18 0.20
Oxprenolol (20) vs. o 0.66 040—1 .07 0.09
R-Oxprenolol (lOWs. placebo . 0.35—0.93 0.0227
iTiiEiBFEEBiBi‘Eiii‘jV;Eli-5555"“WW 73757? 0310880013
S~Oxprenol0l (10) vs. o I 0.71 0464.10 0.13
enolol (20) vs. placebo ! 0.45 0.27—0.73 0.0014
Rilutek (30) vs. enolol (20) 2.07 l.l7—3.67 0.0129
Propanolol (10) vs. S—Oxprcnolol (10) 1.06 0.65—1.74 0.83
Propanolol (10) vs. S-Oxprcnolol (20) 1.77 0.99—3.15 0.0532
R-Oxprenolol (20) vs. S-Oxprenolol 1.32 0.77—2.28 0.3
(20) I
S-Oxprenolol (20) vs. placebo 0.45 0.27-0.73 0.0014
Figure 15 shows the percent survival of male mice that were stered with
S~oxprenolol at dosages of 10 day or 20 mg/kg/day. Other groups of male mice were
administered rilutek at a dosage of30 mg/kg/day; propanolol at a dosage of 10 mg/kg/day;
oxprenolol (racemie) at a dosage of 20 mg/kg/day; R—oxprenolol at a dosage of 10 mg/kg/day
or 20 mg/kg/day; or a placebo. The number of male mice in each population is indicated as
“n” in Figure 15. As shown in Figure 15. male mice receiving S—oxprenolol at a dosage of20
mg/kg/day had longer survival than other groups.
|01 77] The statistical data for Figure 15 is shown below. “HR” refers to hazard ratio.
“95% CI” is confidence interval. “p” refers to p value.
Tabie 2: Statistical data for Figure 15 (for male mice)
ison (dosage in mg/kg/day) p value
Rilutek (30) vs. placebo 1 0.30-1.29
"ii'r'iiiiii'riiiiiiiiifiiifléffiiéééifi """"""""""" 1""""""""""""""""""""
Oxprenoiol (20) vs. placebo I 0.38 0.18-0.80 0.0114
R-Oxprenolol (10)Vs.pla.cebo I 0.49 0.23—0.99 0.0492
R-Oxprenolol (20) vs. placebo I 0.41 0.19—0.86 0.0176
S—Oxpreno'lol (10) vs. placebo I 0.46 0.23—0.92 0.0289
S-Oxprenolol (20) vs. placebo 0.39 0.19—0.83 0.0139
Rilutek (30) vs. S—Oxprenolol (20)
Propanolol (10) vs. S—Oxprenolol (10) . 0.75—3.48
olol (10) vs. S—Oxprenoloi (20) 1 1.98 0.88—4.49 0.099
R-Oxprenolol (20) vs. enoiol 1.24 0.57—2.69 0.58
(20) i
S—Oxprenolol (20) vs. placebo (1.39 0.19—0.83 0.0139
|0178] Figure 16 shows the percent survival of female mice that were administered
with S-oxprenolol at dosages of 10 mg/kglday or 20 mgl'kg/day. Other groups of female mice
were administered rilutek at a dosage of30 mg/kg/day; propanolol at a dosage of 10
mg/kg/day; oxprenolol (racemic) at a dosage of 20 mg/kg/day; R~oxprenolol at a dosage of
mg/kg/day or 20 mg/kg/day; or a placebo. The number of female mice in each population
is indicated as “n” in Figure 16. As shown in Figure 16, female mice ing S~oxprenolol
at a dosage of 20 mg/kg/day had longer survival than other .
The statistical data for Figure 16 is shown below. “HR” refers to hazard ratio.
“95% CI” is confidence interval. “p” refers to p value.
Table 3: Statistical data for Figure 16 (for female mice)
Comparison (dosage in Ing/kg/day) HR 95% CI p value
Rilutck (30) vs. o 0.55-2.15
éiiiii'riliiiiii'i'iij'iié'fBiéiééiié'""""""""""' 'i'J'fi'i """""""""""6363'1'23'9'""""""""""6333 """""""""""""""
Oxprenolol (20) vs. placebo 1.03 0.52-2.02 0.94
R-Oxprenolol (l0) vs. placebo 0.60 i 0.31—1.15 0.13
enolol (20) vs. placebo 0‘41 0.31—1.16 0.13
enolol (10) vs. placebo 0.96 0.53—1.73 0.8.9
S-Oxprenolol (20) vs. placebo 0.53 0227-] .02 0.058
Rilutek (30) vs. S—Oxprenolol (20) 0.92—4.5I
Propanolol (10) vs. S—Oxprenolol (l0) 0.38—1.46 0.39
Propanolol (10) vs. S—Oxprenolol (20) L49 0.67—3.34 1 0.32
enolol (20) vs. S—Oxprenolol 1.26 0.59—2.72 0.55
(30)
S—Oxprenolol (20) vs. placebo 0.53 0.27-1.02 i 0.058
|0180] Figures l7-l9 show changes in disease progression of scores in tested mice.
The disease progression score is based on the JAX SOP (Ludolph AC. Bendotti C. Blaugiund
E, er B, Loffler JP, Martin J, Meininger V, Meyer T, Moussaoui S. Robbereelit W,
Scott S. Silani V, Van Den Berg LH (ENMC Group For The Establishment Of Guidelines
For The Conduct Of Preclinical And Proof Of Concept Studies In ALS/MND Models). 2007,
which is incorporated by reference).
Figure 17 shows the t ofmice that improved from disease progression
ofscore l to score 2 that were administered with S-oxprenolol at dosages of 10 mg/kg/day or
mg/kg/day. Other groups of mice were administered rilutek at a dosage of 30 mg/lrg/day;
propanolol at a dosage of 10 mg/kglday; oxprenolol ic) at a dosage of 20 mg/kg/day;
R-oxprenolol at a dosage of 10 mg/kg/day or 20 mg/kg/day; or a. placebo.
The statistical data for Figure 17 is shown below. "HR" refers to hazard ratio.
“95% CI” is confidence interval. “p” refers to p value.
Table 4: Statistical data for Figure 17 (Progression from score 1 to score 2)
ison e in mg/kg/day) p value
Rilutek vs. placebo 0.48-1.40
"ii'r'iiiiiihliiiii'Jé'fiéi'éfééiiii"""""""""""""""""10.64""""""""""" 03631.66"""""""""""6586'"""""""""""""
Oxprenolol vs. placebo I 0.60 0.36-1.01 0.053
R-Oxprenolol (10)Vs.pla.cebo I 0.47 0.28—0.79 0.0047
R-Oxprenolol (20) vs. o I 0.54 0.32—0.90 0.0176
S—Oxpreno'lol (10) vs. placebo I 0.56 0.35—0.91 0.0189
S-Oxprcnolol (20) vs. placebo 0.5] 0.31—0.87 0.0128
Rilutek \«s, S-Oxprenolol (10) . 0.92—3.08
Rilutek \«s. S—Oxprenoloi (20) . 0.913.29
Propanolol vs. S-Oxprenolol (_ 10) i 1.27 0.73—2.21 0.3
Propanolol vs. S—Oxprenolol (20) 1.49 0.82—2.69 0.19
..........s
R-Oxprenolol (10) vs. S—Oxprenolol 0.73 0.42—1.27 0.27
(10)
S-Oxprenolol s. S-Oxprcnolol 1.17 0.65-2.09 0.60
(20)
Figure 18 shows the percent of mice that improved from disease progression
ofscore 2 to score 3 that were stered with S-oxprenolol at s of 10 mg/kg/day or
mg/kg/day. Other groups of mice were administered rilulek at a dosage 01‘30 mg/kg/day;
propanolol at a dosage of 10 mg/kg/day; oxprenolol (tacemicl) at a dosage of 20 mg/kg/day;
R-oxprcnolol at a dosage of 10 mg/kgx’day or 20 day; or a placebo.
The statistical data for Figure 18 is shown below. “HR” refers to hazard ratio.
“95% CI“ is confidence interval. "1)" refers to p value.
Table 5: Statistical data for Figure 18 (Progression from score 2 to score 3)
Comparison (dosage in mg/kg/day) 95% CI p value
Rilutek vs. placebo 0.37-l .24
Propanolol vs. placebo 0 58-} .69 0 97
Oxprenolol vs. placebo 0.44-l .33 0.35
R-Oxprenolol (l0) vs. placebo 0.59—l .82 0.91
R-Oxprenolol (20) vs. placebo 0.74 0.43—1.27 0.27
S—Oxpreno'lol (10) vs. placebo 1.07 0.64—1.79 0.79
enolol (20) vs. placebo 0.64 0.37-1.12 0.12
Rilutek vs, S-Oxprenolol (l0)
Rilutek vs, S—Oxprenoloi (20) 0.54—2.06
Propanolol vs. S-Oxprenolol (_ l0) 0.48—1.46 0.54
Propanolol vs. S—Oxprenolol (20) 0.81—2.64 0.21
_._...._...
enolol (10) vs. S—Oxprenolol 9 0.87
(10)
S-Oxprenolol (20) vs. S-Oxprcnolol 0.66-2.19 0.55
(20)
Figure [9 shows the percent of mice that improved from disease progression
ofscore 1 to score 3 that were administered with S-oxprenolol at s of 10 mg/kg/day or
day. Other groups of mice were administered rilulek at a dosage ol‘30 mg/kg/day;
propanolol at a dosage of 10 day; oxprenolol (tacemicl) at a dosage of 20 mg/kg/day;
R-oxprcnolol at a dosage of 10 mg/kgx’day or 20 mg/kg/day; or a placebo.
The statistical data for Figure 19 is shown below. “HR” refers to hazard ratio.
“95% CI“ is confidence interval. "1)" refers to p value.
Table 6: tical data for Figure 19 (Progression from score 1 to score 3)
Comparison e in day) p value
Rilutek vs. placebo
éiiiii'riliiiii'Js'fiiiéfééiiii""""""""""""""" l"""""""""""""""""" "631'"""""""""""""""
Oxprenolol vs. placebo I 0.60 0.35-1.01 0.055
R-Oxprenolol (10)Vs.pla.cebo I 0.60 0354.02 0.060
enolol (20) vs. placebo I 0.63 0.37—1.07 0.086
S—Oxprenolol (10) vs. placebo I 0.73 0.45—1.20 0.22
S-Oxprenolol (20) vs. placebo 0.47 0.28—0.81 0.006]
Rilutek \«s. S-Oxprenolol (10) . 0.59—2.14
Rilutek \«s, S—Oxprenoloi (20) . 0.94—4.08
olol vs. S-Oxprenolol (10) i 0.92 0.53—I .57 0.75
Propanolol vs. S—Oxprenolol (20) 1.67 0.91—3.06 0.099
R-Oxprenolol(10)vs. S—Oxprenolol 0.7 0.45—1.36 0.17
(10) j
S-Oxprenolol s. S-Oxprenolol L48 0.79-2.75 0.22
(20)
Example I0. Effects ofS-Oxprenolol compared to enolol and Rilutek
To study the effect of S—oxprenolol on body weight, body weight was
monitored over time. Figure ZOA-ZOC show the change of body weight. in mice administered
S-oxprenolol at a dosage of 20 mg/kg’day or 10 mg/kg/day; R-oxprenolol at a dosage of20
mg/kg/day; rilutek at a dosage of 30 mg/kg/day; or placebo. Figure 20A shows results for all
mice. Figure BOB shows results for male mice. Figure 20C shows results for female mice.
The number of all mice in the population is indicated as “n“ in at the bottom of Figures 20A-
20C.
To study the effect ofthe test compounds on lean body mass, lean mass was
determined at the end of the study. In this experiment. all mice were killed using the 30
seconds endpoint and hence all mice were equally diseased at the end of the study. Figures
20D-20F Show the change in lean body mass (in grams) of mice that were administered S—
oxprenolol at a dosage of20 mg/kg’day or 10 mgkg/day; R—oxprenolol at a dosage of20
mg/kg/day; rilutek at a dosage of 30 mg/kgr’day; or placebo. Figure 20D shows results for all
mice. Figure 2013 shows results for male mice. Figure 20F shows results for female mice.
The number of all mice in the population is indicated as “n” in at the bottom of Figures 20D-
20F.
To study the effect ol‘ the test compounds on fat mass, the fat mass were
determined at the end of the study. Figures 2OG-20l show the change in fat mass (in. grams)
of mice administered S-oxprenolol at a dosage of 20 mg/kg/day or 10 day; R-
oxprenolol at a dosage of 20 mg’kg/day; rilutek at a dosage of3l) mg/kg/day; or placebo.
Figure 20G shows results for all mice. Figure 20H shows results for male mice. Figure 20l
shows results for female mice. The number of all mice in the population is indicated as “n"
in at the bottom ofFigures I.
Figures 2lA—21 C show results for heart weight at the end of the study.
Figures 21 A—Zl C show the heart weight (in rams) of mice administered S-oxprcnolol at
a dosage of 20 mg/kg/day or 10 mg/kg/day; R—oxprenolol at a dosage of20 mg/kg/day;
rilutek at a dosage of3() mg/kg/day; or placebo. Figure 21 A shows results for all mice.
Figure 21B shows results for male mice. Figure 21C shows results for female mice. The
number of all mice in the population is ted as “n” in at the bottom of Figures 2lA-21C.
Figures ‘2lD-21F show results for gastrocnemius muscle weight at the end of
the study. Figures 21D-21F show the gastrocnemius muscle weight (in milligrams) of mice
administered S-oxprenolol at a dosage of2l) rug/kg/day or l0 rug/kg/day; R—oxprenolol at a
dosage of 20 mg/ltg/day; rilutek at a dosage ol‘30 mg/kg/day; or placebo. Figure 21D shows
s for all mice. Figure 21E shows results for male mice. Figure 21F shows results for
female mice. The number of all mice in the population is indicated as “n" in at the bottom of
Figures 20D-20F.
s l Show results for tibialis muscle weight at the end of the
study. Figures 210-2” show the tibialis muscle weight (in milligrams) ofmice stered
S—oxprenolol at a dosage ol'20 mg/kg/day or 10 mg/kg/day; R—oxprenolol at a dosage ol’20
mg/kg/day: rilutek at a dosage of 30 mg/kg/day; or placebo. Figure 21 G shows s for all
mice. Figure 21 H shows results for male mice. Figure 21 I shows results for female mice.
The number of all mice in the population is indicated as “n” in at the bottom of Figures 2lG-
2] I.
The following tables show results for mice administered with S—oxprenolol at
a dosage of 20 mg/kg/day or 10 mg/kg/day; R—oxprenolol at a dosage of 20 mg/kg/day or 10
mg/kg/day; rilutck at a dosage of 30 mg/kgz’day; propanolol at a dosage of 10 mgdx’g/day;
oxprenolol (racemic) at a dosage of 20 mg/kg/day; or placebo. The results for delta body
weight, delta lean mass, delta fat mass, average delta body weight, e delta lean mass,
average delta fat mass, heart mass, gastrocnemius mass, soleus mass, EDL, and BAT were
obtained with tests according the examples herein.
Table 7: Data for all mice administered with S-oxprenolol, R—oxprenolol. rilutek,
propanolol, oxprenolol (racemic), or placebo.
placebo 30 mg/kg’d l0 mg/kg/d 20 m g’kg/
rilutek propanolol oxprenolol
A body wcight [g] 5.51i0.34 -5.10i0.35 0.42 -5.59i0.48
A lean mass [g] -3.7l.+.0.27* -4.S9$—0.26 -4.67.Jc0.42
A fat mass [g] .15 -l.91i0.l5 4.8212025 -l.493c0.l2
Average A body - l 53 72522.2 :‘rl5.2 ~127.6i:10.6 -lZ3.6aEl2.3
weight [mg/day]
Average A lean 435.91195 —92.31i15.84 —l L74 —l()2.()il0.7
mass [mg/day]
Average A fat -35.6t3.8 -50.li6.l* -43.9i5r5 -33.li2.6
mass [mg/day]
Heart [mg] l 005:3.4 23 104.0% ,2 l 00.25 .2
gastroenemius 477:3,0 55.2i3.() 52.4233 52.2223
[mg]
soleus [mg] 5.851022 39 5.60:0.28 4.99;;036"
EDL [mg] 6.94:”.025 6.7li0.32 7rlli0.37 7.24:0.41
BAT [mg] 41 212.4 53.7:2.9** 45. li2.9 40.63623
Table 7 (cont): Data for all mice stered with S-oxprenolol. R-oxprenolol, rilutek,
propanolol, oxprcnolol (raccmic), or placebo.
““““““““““““““““““““““i
Omgkbd 20makgd 10mgkgdzommd
R-oxprenolol enolol S—oxprenolol S—oxprenolol
A body weight [g] ‘:0.39 5.211039 5.401043 -5.561:0.47
A lean mass [g] 032 460120.28 —313 1 210.33W l:0.4l
A {at mass [g] 0. l5 -l.59_L0.15 4.261.014 ~l .56i0.13
Average A body -146.lill.l 411.0194 43:11.6 -99.4:9.7""‘°-°64
weight [mg/day]
Average A lean -125.8il2.7 06616.4 —89.6i9.l * -93.3:7.5*
mass y]
Average A fat mass ~38.3:£:4.2 -32.61:3.0 0.9.413] —29.8:l:3.6
[mg/day]
Heart [mg] 101.32.? lOO.7::3.8 108.6:53 lO4.li3.5
gash‘ocnemius [mg] SO.8:3.3 47.0i2.6 55.1i4.0 50.]:29
soleus [mg] 4.49:0.36** 5.49i034 5.89i035 6.42:0.39
EDL [mg] .47 5.89.+0,31* 7..18+0.34 7.791029%“
BAT [mg] 44.5.7 . 43,314.! 46.885 43.7133
ASHEiiéfiiiiééiiéé’A'[{{{g7li.1y]. air'é'r'é'gé'aé'lfai'fié‘r‘fié‘i?Ell—1753053 diEéEsE'55&3;EEC?Efié‘fiéér"éigiififlfii'iiifiéifi,‘"""
BAT: brown adipose tissue, *rp<’0.05, ”t p'L‘Ofll vs placebo, ##1'11 p<.0.00l vs lOmg/kg/d propanolol, $1 p<10.05
vs wing/kg/d R-oxprcnolol. *+--=-+: p<0.00] vs 30 mg/kg/d rilutck
Table 8: Data for male mice administered with S-oxprenolol, R-oxprenolol, rilutek,
propanolol, oxprenolol (racemic), or placebo.
placebo 30 mg/kgfd tilulek l0 mg’kg/d 20 d
propanolol oxpi‘enolol
_______._______4
A body weight [g] —6.81:0.54 0.43 —6.l l::0,54 -5.94::0.77
_______A________+._______._______,________
A lean mass [g] 6.4454139 ~4. .38* 6.0632037 -5.64:E0.68
mm?“
A fat mass [g] -l.66:i:0.27 2.0932022 —l.99: 20.26 433120.13
————.—.
Average A body “2158:2364 fl7.9* ~l42.7i15.9 —124.8d:20.7
weight [mg/day]
Average A lean -l78. 1261.9 —S7.4:&:2 [ *
. l 41861106 —1 19.421: 17.7
mass [mg-’day]
Average A fat mass -40.5:6.8 -57.5=l 1.3 —Sl.9::6.9 -28.3::3.l
1mg/da11
I-lean [mg] ll7.9i3.4 115.6314 ll3.5i4.6 110.2i2.9
gastrocncmius [mg] .3 585:4.9 63.3i3.6 54.7139
soleus [mg] 6.03L0.32 5-72;0.64 5.63i038 5.2 H051
EDL [mg] 7.83:0.32 7.20i0.5l 7.941055 7.49i0.72
BAT [mg] 449:3!) 54.8:39 48.7i5.l 45.7::3.6
Table 8 (cont): Data for male mice administered with S~oxpreuoloL enolol. rilutek.
olol, oxprenolol (racemic), or placebo.
'JI \l
d 20 g/d 10 mg/kg/d 20 mgflkg/d
R-oxprenolol R—oxprenolol S—oxprenolol S-oxprenolol
A body weight [g] —6.515:0.65 -5.53::0.57 65710.57 —6.36:£.67
A lean mass [g] -5 55i0.47 -5.12i0.38 -3.67::O.49**" 6.34:0.56
A fat mass [g] —l 5720.21 -l.4&:0.16 ~1.44:,0.19 -l.78t0.28
e A body ~153.5:t 16 1 ~116.0:‘::l3,7* 450312145 ~115l7:112.6*
weight [mg/day]
Average A lean ~129.7i9.9 :1:8.5 :d:13.9 853:1 1015*
mass y]
Average A [at mass -37.4:‘:6 4 49.9135 43.615 7 ~32.l:15 4
[mg/day] ;
Heart [mg] 107.4L3.4* 112.0:411 '12216i8.8 4115
gastrocnemius [mg] 538:5.1 49.91330 59.1:6.6 53.l::4.3
soleus [mg] 4.74:0.51* 5.84:0.45 604:0.53 6.58i0.61
EDL [mg] 6.5920161 5.31:0.42*** 7.23:0.47 39W
BAT [mg] 467:4.9 53916.8 532:5.0 46.5281)
A: delta, average A [mg/day]: average delta per day alive after disease onset. EDL: cxteusor digiionlm longus,
BAT: brown adipose tissue. *:p<0.05, **: p<:0.0l, ***: p<0.001 vs placebo. #: p<0.05 vs lOmg/kgr’d propanelol,
$$$z p<0.001 vs 20mg/kgd R—oxpx'enolol
Table 9: Data for female mice administered with S-oxprenolol, R—oxprenolol, riluIek,
propanolol, exprenolol (racemic). or placebo.
placebo 30 mg/k‘g/d rilutek 10 mg/‘kg/d 2O mg/kg/d
propauolol oxprenelol
A body weight [g] -4v55i0.32 -4.49i0.46 -5.66:t0.66 '5.27i0.6l
A lean mass [g] -3.42i0.25 -3.3 li0.37 -4.70i0.37** -3.76:t0.42
A fat mass [2,] ~1161i0.15 -l.76i0.21 -l.65i0.44 -1 .6421:0.2.l
Average A body 20.6 -l'22,9::25.7 -l l 1.3i.l3.2 -122.5il4.7
weight [mg/day]
Average A lean —84.3 1:119 -96.9i:24.2 ~91.2:18 “a -85.81:11.6
mass [mg/day]
Average A ("at mass —“7"5.2:4.6 «12.216 1 ~30.9i8.3 3775i”: 7
[mg/day]
-‘- —-4
Heart [mg] 86.1il.5 91.4:23 7" 895:2 4
ocnemius [mg] 21.2i2.9 5415.8“ 40.653 49.5:2 l
soleus [mg] 5.721.030 5.26:&:().48 5571:1143 4.76: O 52
EDL [mg] 6291:0128 6 28¢ 39 ::O.37 6973:036
BAT [mg] 38.853!) 53 7&45’L 41212.2 35224.1
U! DO
A definition of a specific embodiment of the ion as claimed herein
follows.
According to an embodiment of the invention, there is provided use of a
composition comprising oxprenolol or a pharmaceutically acceptable salt thereof, wherein
oxprenolol has one chiral center and the ition comprises an enantiomeric excess of
at least 60% of S-oxprenolol, in the manufacture of a medicament for treating
amyotrophic lateral sclerosis in an dual having amyotrophic lateral sclerosis.
Claims (10)
1. Use of a composition comprising oxprenolol or a pharmaceutically acceptable salt thereof, wherein oxprenolol has one chiral center and the ition ses an enantiomeric excess of at least 60% of S-oxprenolol, in the cture of a medicament for treating amyotrophic lateral sclerosis in an individual having amyotrophic lateral sclerosis.
2. The use of claim 1, wherein survival is prolonged, pment of amyotrophic lateral sclerosis is delayed, loss of lean mass is prevented, quality of life is improved and/or muscle wasting is prevented.
3. The use of claim 1 or 2, wherein the composition ses an enantiomeric excess of at least 80% of S-oxprenolol.
4. The use of claim 1 or 2, wherein the composition comprises an enantiomeric excess of at least 99% of S-oxprenolol.
5. The use of claim 1 or 2, wherein the composition comprises an enantiomeric excess of at least 99.9% of S-oxprenolol.
6. The use of any one of claims 1 to 5, wherein the amyotrophic lateral sclerosis is sporadic amyotrophic lateral sclerosis, familial amyotrophic lateral sclerosis, Western Pacific amyotrophic lateral sclerosis, juvenile amyotrophic lateral sclerosis, or ya Disease.
7. The use of any one of claims 1 to 5, wherein the amyotrophic lateral sclerosis is progressive bulbar palsy (PBP), ssive muscular atrophy (PMA), primary lateral sclerosis (PLS), or ALS with multi-system involvement.
8. The use of any one of claims 1 to 7, wherein the composition is formulated to be administered orally.
9. The use of any one of claims 1 to 8, wherein the amount of S-oxprenolol in the ition is 80 to 160 mg daily.
10. The use of any one of claims 1 to 9, wherein the composition is formulated to be administered daily or twice daily.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361786235P | 2013-03-14 | 2013-03-14 | |
US61/786,235 | 2013-03-14 | ||
PCT/AU2014/000274 WO2014138814A1 (en) | 2013-03-14 | 2014-03-14 | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ713051A NZ713051A (en) | 2020-09-25 |
NZ713051B2 true NZ713051B2 (en) | 2021-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2690061T3 (en) | Compositions to treat Parkinson's disease | |
EA010430B1 (en) | Combination of an nmda receptor antagonists and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | |
CN113271936A (en) | Method for treating neurological and psychiatric disorders | |
US11938102B2 (en) | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | |
TW201924668A (en) | Deuterated analogs of D-serine and uses thereof | |
AU2022241503A1 (en) | S-enantiomerically enriched compositions of beta blockers for treating muscle weakness | |
EP1482921A1 (en) | Methods of treating attention deficit/hyperactivity disorder (adhd) | |
JP2017533967A (en) | Method for treating Huntington's disease using cysteamine composition | |
CA3153305A1 (en) | Methods for treating neurological disorders with ?1a-ar partial agonists | |
US7816370B2 (en) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism | |
AU2003267557B2 (en) | Treatment of dyskinesia | |
NZ713051B2 (en) | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | |
EP4228642A1 (en) | Administration of antipurinergic compositions for treating nervous system disorders | |
US20240226069A1 (en) | Vafidemstat for use in treating autism spectrum disorders | |
WO2024006841A2 (en) | Compositions for weight loss and cancer treatment |